BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550. [PMID: 17167137 DOI: 10.1056/nejmoa061884] [Cited by in Crossref: 4183] [Cited by in F6Publishing: 1752] [Article Influence: 261.4] [Reference Citation Analysis]
Number Citing Articles
1 Hoverman JR. Rethinking clinical oncology drug research in an era of value-based cancer care: A role for chemotherapy pathways. Cancer Med 2020;9:5306-11. [PMID: 32524722 DOI: 10.1002/cam4.3193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR, Vokes EE. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol 2011;29:4436-41. [PMID: 21969504 DOI: 10.1200/JCO.2011.35.6923] [Cited by in Crossref: 55] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
3 Agostara B, Carruba G, Usset A. The management of cancer in the elderly: targeted therapies in oncology. Immun Ageing 2008;5:16. [PMID: 19116012 DOI: 10.1186/1742-4933-5-16] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
4 Chen JH, Yang JL, Chou CY, Wang JY, Hung CC. Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer. Sci Rep 2018;8:9686. [PMID: 29946182 DOI: 10.1038/s41598-018-27994-x] [Reference Citation Analysis]
5 Marr AS, Ganti AK. Advanced lung cancer in the older patient: is there a role for bevacizumab? J Thorac Dis 2012;4:629-30. [PMID: 23205289 DOI: 10.3978/j.issn.2072-1439.2012.09.07] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Van Veldhuizen PJ, Hussey M, Lara PN Jr, Mack PC, Gandour-Edwards R, Clark JI, Lange MK, Crawford DE. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312. Am J Clin Oncol 2009;32:453-9. [PMID: 19487915 DOI: 10.1097/COC.0b013e3181925176] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
7 Ahn MJ, Sun JM, Ahn JS, Park K. The effectiveness of maintenance pharmacotherapies for non-small cell lung cancer. Clin Med Insights Oncol 2012;6:253-62. [PMID: 22745566 DOI: 10.4137/CMO.S8001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Yu B, Lu Y, Gao F, Jing P, Wei H, Zhang P, Liu G, Ru N, Cui G, Xu X, Sun C, Guan C, Che Y, Wu Y, Ma Z, Fu Q, Liu J, Wang HY. Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy. Lung Cancer (Auckl) 2015;6:1-11. [PMID: 28210146 DOI: 10.2147/LCTT.S70679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
9 Yélamos J, Galindo M, Navarro J, Albanell J, Rovira A, Rojo F, Oliver J. Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors. Oncoimmunology 2016;5:e1065370. [PMID: 26942084 DOI: 10.1080/2162402X.2015.1065370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
10 Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012;2:a006577. [PMID: 23028128 DOI: 10.1101/cshperspect.a006577] [Cited by in Crossref: 132] [Cited by in F6Publishing: 124] [Article Influence: 13.2] [Reference Citation Analysis]
11 Ge C, Li R, Song H, Geng T, Yang J, Tan Q, Song L, Wang Y, Xue Y, Li Z, Dong S, Zhang Z, Zhang N, Guo J, Hua L, Chen S, Song X. Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC. BMC Cancer 2017;17:884. [PMID: 29268708 DOI: 10.1186/s12885-017-3859-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
12 Sumiyoshi I, Okabe T, Togo S, Takagi H, Motomura H, Ochi Y, Shimada N, Haraguchi M, Shibayama R, Fujimoto Y, Watanabe J, Iwai M, Kadoya K, Iwakami SI, Takahashi K. High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study. J Transl Med 2021;19:92. [PMID: 33639962 DOI: 10.1186/s12967-021-02761-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Khan P, Siddiqui JA, Lakshmanan I, Ganti AK, Salgia R, Jain M, Batra SK, Nasser MW. RNA-based therapies: A cog in the wheel of lung cancer defense. Mol Cancer 2021;20:54. [PMID: 33740988 DOI: 10.1186/s12943-021-01338-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Schultz L, Mikkelsen T. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol 2010;99:237-42. [PMID: 20151176 DOI: 10.1007/s11060-010-0121-0] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 5.0] [Reference Citation Analysis]
15 Alt-Epping B, Nauck F. [Implications of modern anticancer therapies for palliative care concepts]. Schmerz 2010;24:633-41. [PMID: 20882301 DOI: 10.1007/s00482-010-0940-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Takahashi O, Komaki R, Smith PD, Jürgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res 2012;18:1641-54. [PMID: 22275507 DOI: 10.1158/1078-0432.CCR-11-2324] [Cited by in Crossref: 40] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
17 Wang H, Zhu H, Kong L, Yu J. Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review. Onco Targets Ther 2016;9:4639-44. [PMID: 27555784 DOI: 10.2147/OTT.S101241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Furqan M, Abu-hejleh T, Stephens LM, Hartwig SM, Mott SL, Pulliam CF, Petronek M, Henrich JB, Fath MA, Houtman JC, Varga SM, Bodeker KL, Bossler AD, Bellizzi AM, Zhang J, Monga V, Mani H, Ivanovic M, Smith BJ, Byrne MM, Zeitler W, Wagner BA, Buettner GR, Cullen JJ, Buatti JM, Spitz DR, Allen BG. Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer. Redox Biology 2022. [DOI: 10.1016/j.redox.2022.102318] [Reference Citation Analysis]
19 Iyer G, Milowsky MI, Bajorin DF. Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert Rev Anticancer Ther 2010;10:1917-32. [PMID: 21110758 DOI: 10.1586/era.10.182] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
20 Qin S, Yi M, Jiao D, Li A, Wu K. Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma. J Cancer 2020;11:153-67. [PMID: 31892982 DOI: 10.7150/jca.34693] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
21 Li BT, Barnes TA, Chan DL, Naidoo J, Lee A, Khasraw M, Marx GM, Kris MG, Clarke SJ, Drilon A, Rudin CM, Pavlakis N. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Lung Cancer 2016;102:21-7. [PMID: 27987583 DOI: 10.1016/j.lungcan.2016.10.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
22 Stewart DJ, Behrens C, Roth J, Wistuba II. Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancer. Lung Cancer 2011;71:217-23. [PMID: 20627364 DOI: 10.1016/j.lungcan.2010.05.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
23 Höpfner M, Schuppan D, Scherübl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008; 14(1): 1-14 [PMID: 18176955 DOI: 10.3748/wjg.14.1] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 74] [Article Influence: 5.1] [Reference Citation Analysis]
24 Kastritis E, Charidimou A, Varkaris A, Dimopoulos MA. Targeted therapies in multiple myeloma. Target Oncol 2009;4:23-36. [PMID: 19343299 DOI: 10.1007/s11523-008-0102-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
25 Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. 2017;20:185-204. [PMID: 28361267 DOI: 10.1007/s10456-017-9552-y] [Cited by in Crossref: 215] [Cited by in F6Publishing: 220] [Article Influence: 43.0] [Reference Citation Analysis]
26 Blumenthal GM, Zhang L, Zhang H, Kazandjian D, Khozin S, Tang S, Goldberg K, Sridhara R, Keegan P, Pazdur R. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis. JAMA Oncol 2017;3:e171029. [PMID: 28617920 DOI: 10.1001/jamaoncol.2017.1029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
27 Bonanno L, Favaretto A, Rugge M, Taron M, Rosell R. Role of genotyping in non-small cell lung cancer treatment: current status. Drugs 2011;71:2231-46. [PMID: 22085382 DOI: 10.2165/11597700-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
28 Mortimer J, Zonder HB, Pal SK. Lessons learned from the bevacizumab experience. Cancer Control 2012;19:309-16. [PMID: 23037498 DOI: 10.1177/107327481201900407] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
29 Lu WJ, Peng W, Sun QQ, Li YH, Chen B, Yu LT, Xu YZ, Wang SY, Zhao YL. #2714, a novel active inhibitor with potent G2/M phase arrest and antitumor efficacy in preclinical models. Cell Death Discov 2018;4:24. [PMID: 29531821 DOI: 10.1038/s41420-018-0032-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Taleb M, Mohammadkhani N, Bahreini F, Ovais M, Nie G. Modulation of Tumor Vasculature Network: Key Strategies. Small Structures. [DOI: 10.1002/sstr.202100164] [Reference Citation Analysis]
31 Herder G, Codrington H, Colder CD, Aerts JG. Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases. Lung Cancer (Auckl) 2013;4:55-9. [PMID: 28210135 DOI: 10.2147/LCTT.S45309] [Reference Citation Analysis]
32 Liang Y, Tian WY, Huang JJ, Gao LX, Fan XH. MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells. Oncol Lett 2021;21:482. [PMID: 33968198 DOI: 10.3892/ol.2021.12743] [Reference Citation Analysis]
33 Takagi Y, Toriihara A, Nakahara Y, Yomota M, Okuma Y, Hosomi Y, Shibuya M, Okamura T. Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study. PLoS One 2013;8:e59700. [PMID: 23555751 DOI: 10.1371/journal.pone.0059700] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
34 Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15:325-340. [PMID: 29508855 DOI: 10.1038/nrclinonc.2018.29] [Cited by in Crossref: 440] [Cited by in F6Publishing: 443] [Article Influence: 110.0] [Reference Citation Analysis]
35 Vitale SG, Laganà AS, Capriglione S, Angioli R, La Rosa VL, Lopez S, Valenti G, Sapia F, Sarpietro G, Butticè S, Tuscano C, Fanale D, Tropea A, Rossetti D. Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives. Int J Mol Sci 2017;18:E1100. [PMID: 28531111 DOI: 10.3390/ijms18051100] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
36 Metzenmacher M, Christoph DC. Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer. J Thorac Dis 2016;8:E1254-6. [PMID: 27867601 DOI: 10.21037/jtd.2016.10.26] [Reference Citation Analysis]
37 Buttigliero C, Bertaglia V, Novello S. Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer. Transl Lung Cancer Res 2016;5:610-27. [PMID: 28149756 DOI: 10.21037/tlcr.2016.09.03] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
38 Ferreira M, Secher T, Heuze-Vourc'H N, Reckamp KL. Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. Pharmaceutics 2021;13:912. [PMID: 34205484 DOI: 10.3390/pharmaceutics13060912] [Reference Citation Analysis]
39 Ch’ang HJ. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol 2015; 7(16): 2029-2040 [PMID: 26261692 DOI: 10.4254/wjh.v7.i16.2029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
40 Zhang F, Huang D, Zhao L, Li T, Zhang S, Zhang G, Yuan F, Zhang J, Zhang Y, Zhao Z, Cui L, Zhao J, Wang G, Cai S, Bai Y, Wang J, Hu Y. Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy. Ther Adv Med Oncol 2020;12:1758835920936882. [PMID: 32670420 DOI: 10.1177/1758835920936882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Dearing KR, Sangal A, Weiss GJ. Maintaining clarity: Review of maintenance therapy in non-small cell lung cancer. World J Clin Oncol 2014; 5(2): 103-113 [PMID: 24829857 DOI: 10.5306/wjco.v5.i2.103] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
42 Li L, Li G, Rao B, Dong AH, Liang W, Zhu JX, Qin MP, Huang WW, Lu JM, Li ZF, Wu YZ. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population. Sci Rep 2020;10:15567. [PMID: 32968172 DOI: 10.1038/s41598-020-72649-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
43 Masuda C, Yanagisawa M, Yorozu K, Kurasawa M, Furugaki K, Ishikura N, Iwai T, Sugimoto M, Yamamoto K. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model. Int J Oncol 2017;51:425-34. [PMID: 28627678 DOI: 10.3892/ijo.2017.4036] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
44 Cheng JD, Chai LX, Zhao ZP, Hao YY, Li S. Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor. Cancer Manag Res 2020;12:5641-50. [PMID: 32765067 DOI: 10.2147/CMAR.S253366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C, Rizvi S. Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2009;2:31. [PMID: 19635146 DOI: 10.1186/1756-8722-2-31] [Cited by in Crossref: 112] [Cited by in F6Publishing: 108] [Article Influence: 8.6] [Reference Citation Analysis]
46 Guirgis HM. The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective. J Immunother Cancer 2018;6:15. [PMID: 29463302 DOI: 10.1186/s40425-018-0320-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
47 Tanaka S, Sakamori Y, Niimi M, Hazama M, Kim YH, Yanagihara K. Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST). Trials 2011;12:120. [PMID: 21569411 DOI: 10.1186/1745-6215-12-120] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
48 Owonikoko TK, Ragin C, Chen Z, Kim S, Behera M, Brandes JC, Saba NF, Pentz R, Ramalingam SS, Khuri FR. Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis. Oncologist 2013;18:600-10. [PMID: 23635558 DOI: 10.1634/theoncologist.2012-0480] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
49 Ohta M, Kawabata T, Yamamoto M, Tanaka T, Kikuchi H, Hiramatsu Y, Kamiya K, Baba M, Konno H. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surg Today 2009;39:1046-53. [PMID: 19997799 DOI: 10.1007/s00595-009-4020-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
50 Stinchcombe TE, Socinski MA, Lee CB, Hayes DN, Moore DT, Goldberg RM, Dees EC. Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. J Thorac Oncol 2008;3:521-6. [PMID: 18449006 DOI: 10.1097/JTO.0b013e31816de2a7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
51 Vadakara J, Borghaei H. Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers Med 2012;5:113-23. [PMID: 23226067 DOI: 10.2147/PGPM.S24258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 14] [Article Influence: 0.1] [Reference Citation Analysis]
52 Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget 2013;4:118-27. [PMID: 23435217 DOI: 10.18632/oncotarget.763] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
53 Sasajima J, Mizukami Y, Sugiyama Y, Nakamura K, Kawamoto T, Koizumi K, Fujii R, Motomura W, Sato K, Suzuki Y, Tanno S, Fujiya M, Sasaki K, Shimizu N, Karasaki H, Kono T, Kawabe J, Ii M, Yoshiara H, Kamiyama N, Ashida T, Bardeesy N, Chung DC, Kohgo Y. Transplanting normal vascular proangiogenic cells to tumor-bearing mice triggers vascular remodeling and reduces hypoxia in tumors. Cancer Res 2010;70:6283-92. [PMID: 20631070 DOI: 10.1158/0008-5472.CAN-10-0412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
54 Nadler E, Yu E, Ravelo A, Sing A, Forsyth M, Gruschkus S. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. Oncologist 2011;16:486-96. [PMID: 21441299 DOI: 10.1634/theoncologist.2010-0287] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
55 Kenmotsu H, Serizawa M, Koh Y, Isaka M, Takahashi T, Taira T, Ono A, Maniwa T, Takahashi S, Mori K, Endo M, Abe M, Hayashi I, Nakajima T, Ohde Y, Yamamoto N. Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays. BMC Cancer 2014;14:786. [PMID: 25348872 DOI: 10.1186/1471-2407-14-786] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
56 Wang Y, Li X, Zhang L, Li M, Dai N, Luo H, Shan J, Yang X, Xu M, Feng Y, Xu C, Qian C, Wang D. A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homology 3 mimetic gossypol combined with docetaxel and cisplatin for advanced non-small cell lung cancer with high expression of apurinic/apyrimidinic endonuclease 1. Invest New Drugs 2020;38:1862-71. [PMID: 32529467 DOI: 10.1007/s10637-020-00927-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Savas P, Hughes B, Solomon B. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis 2013;5 Suppl 5:S579-92. [PMID: 24163750 DOI: 10.3978/j.issn.2072-1439.2013.08.52] [Cited by in F6Publishing: 22] [Reference Citation Analysis]
58 Protopapa M, Kouloulias V, Nikoloudi S, Papadimitriou C, Gogalis G, Zygogianni A. From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC. J Oncol 2019;2019:3267409. [PMID: 30853981 DOI: 10.1155/2019/3267409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
59 Riaz MK, Bal S, Wise-Draper T. The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer. J Surg Oncol 2016;114:323-8. [PMID: 27377825 DOI: 10.1002/jso.24333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
60 Bhardwaj B, Revannasiddaiah S, Bhardwaj H, Balusu S, Shwaiki A. Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma. Ann Transl Med 2016;4:50. [PMID: 26904572 DOI: 10.3978/j.issn.2305-5839.2015.10.35] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
61 Cardó-Vila M, Marchiò S, Sato M, Staquicini FI, Smith TL, Bronk JK, Yin G, Zurita AJ, Sun M, Behrens C, Sidman RL, Lee JJ, Hong WK, Wistuba II, Arap W, Pasqualini R. Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer: Analysis of Clinical Samples and BMTP-11 Preclinical Activity. Am J Pathol 2016;186:2162-70. [PMID: 27317903 DOI: 10.1016/j.ajpath.2016.04.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
62 Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 2010;9:176-82. [PMID: 20009575 DOI: 10.4161/cbt.9.3.10635] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
63 Masuda R, Kijima H, Nito M, Wada A, Matsuzaki T, Ikoma Y, Nakazato K, Masuda D, Tanaka M, Kobayashi H, Inokuchi S, Iwazaki M. Lymphatic invasion is a significant indicator of poor patient prognosis in lung squamous cell carcinoma. Mol Med Rep 2017;15:2067-73. [PMID: 28260029 DOI: 10.3892/mmr.2017.6256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
64 Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, Zhou Q. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 2012;7:e35629. [PMID: 22539986 DOI: 10.1371/journal.pone.0035629] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
65 Aggarwal C, Borghaei H. Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. Oncologist 2017;22:700-8. [PMID: 28408617 DOI: 10.1634/theoncologist.2016-0345] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
66 Caporarello N, Lupo G, Olivieri M, Cristaldi M, Cambria MT, Salmeri M, Anfuso CD. Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions (Review). Mol Med Rep 2017;16:4393-402. [PMID: 28791360 DOI: 10.3892/mmr.2017.7179] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
67 Yin C, Ma G, Rong Y, Kong P, Yang Q, Jiang C, Liao F, Zhang B, He W, Xia L. The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer. J Cancer 2016;7:1901-6. [PMID: 27698931 DOI: 10.7150/jca.15802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
68 Liang Y, Zhang Y, Wang G, Li Y, Huang W. Penduliflaworosin, a Diterpenoid from Croton crassifolius, Exerts Anti-Angiogenic Effect via VEGF Receptor-2 Signaling Pathway. Molecules 2017;22:E126. [PMID: 28098802 DOI: 10.3390/molecules22010126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
69 Olson JJ, Paleologos NA, Gaspar LE, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Patchell RA, Ryken TC, Kalkanis SN. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol 2010;96:115-42. [PMID: 19957013 DOI: 10.1007/s11060-009-0058-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
70 Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285. [PMID: 21252716 DOI: 10.1097/jto.0b013e318206a221] [Cited by in Crossref: 2694] [Cited by in F6Publishing: 1213] [Article Influence: 244.9] [Reference Citation Analysis]
71 Laslett NF, Park S, Masters GA, Biggs DD, Schneider CJ, Misleh JG, Suppiah K, Simpson PS, Grubbs S, Wozniak TF, Guarino M. Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. Cancer Med 2018. [PMID: 29905018 DOI: 10.1002/cam4.1569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
72 Eikesdal HP, Kalluri R. Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol 2009;19:310-7. [PMID: 19524042 DOI: 10.1016/j.semcancer.2009.05.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
73 Shao R, Taylor SL, Oh DS, Schwartz LM. Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization. Oncotarget 2015;6:40507-18. [PMID: 26439689 DOI: 10.18632/oncotarget.5943] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
74 Yuan D, Xia M, Meng G, Xu C, Song Y, Wei J. Anti-angiogenic efficacy of 5'-triphosphate siRNA combining VEGF silencing and RIG-I activation in NSCLCs. Oncotarget 2015;6:29664-74. [PMID: 26336994 DOI: 10.18632/oncotarget.4869] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
75 Zhou G. Tobacco, air pollution, environmental carcinogenesis, and thoughts on conquering strategies of lung cancer. Cancer Biol Med 2019;16:700-13. [PMID: 31908889 DOI: 10.20892/j.issn.2095-3941.2019.0180] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
76 Esposito L, Conti D, Ailavajhala R, Khalil N, Giordano A. Lung Cancer: Are we up to the Challenge? Curr Genomics 2010;11:513-8. [PMID: 21532835 DOI: 10.2174/138920210793175903] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 6.4] [Reference Citation Analysis]
77 Zhang XL, Cao XY, Lai RC, Xie MX, Zeng WA. Puerarin Relieves Paclitaxel-Induced Neuropathic Pain: The Role of Nav1.8 β1 Subunit of Sensory Neurons. Front Pharmacol 2018;9:1510. [PMID: 30666203 DOI: 10.3389/fphar.2018.01510] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
78 McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A, Lee DY, Lucien L, Brannigan BW, Ulkus LE, Ma XJ, Erlander MG, Haber DA, Sharma SV, Settleman J. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res 2009;69:3937-46. [PMID: 19366796 DOI: 10.1158/0008-5472.CAN-08-4327] [Cited by in Crossref: 75] [Cited by in F6Publishing: 43] [Article Influence: 5.8] [Reference Citation Analysis]
79 Zhang R, Jia M, Xue H, Xu Y, Wang M, Zhu M, Sun M, Chang J, Wei Q. Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy. Sci Rep 2017;7:10702. [PMID: 28878296 DOI: 10.1038/s41598-017-10800-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
80 Yokoi T, Torii Y, Katashiba Y, Sugimoto H, Tanijiri T, Ogata M, Inagaki N, Kibata K, Hayashi M, Niki M, Shimizu T, Miyara T, Kurata T, Nomura S. Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer. Oncol Lett 2014;8:2453-7. [PMID: 25364406 DOI: 10.3892/ol.2014.2552] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
81 Zeng DX, Wang CG, Huang JA, Jiang JH. Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation. Onco Targets Ther 2017;10:4269-72. [PMID: 28894382 DOI: 10.2147/OTT.S139520] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
82 Tanase C, Popescu ID, Enciu AM, Gheorghisan-Galateanu AA, Codrici E, Mihai S, Albulescu L, Necula L, Albulescu R. Angiogenesis in cutaneous T-cell lymphoma - proteomic approaches. Oncol Lett 2019;17:4060-7. [PMID: 30944599 DOI: 10.3892/ol.2018.9734] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
83 Park K, Kim JH, Cho EK, Kang JH, Shih JY, Zimmermann AH, Lee P, Alexandris E, Puri T, Orlando M. East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL). Cancer Res Treat 2016;48:1177-86. [PMID: 26910471 DOI: 10.4143/crt.2015.401] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
84 Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Coan A, Threatt S, Friedman AH, Friedman HS. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 2011;117:5351-8. [PMID: 21590689 DOI: 10.1002/cncr.26188] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 5.9] [Reference Citation Analysis]
85 Tiwari R, Sethiya NK, Gulbake AS, Mehra NK, Murty USN, Gulbake A. A review on albumin as a biomaterial for ocular drug delivery. Int J Biol Macromol 2021;191:591-9. [PMID: 34562538 DOI: 10.1016/j.ijbiomac.2021.09.112] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Hawkins-Daarud A, Rockne RC, Anderson AR, Swanson KR. Modeling Tumor-Associated Edema in Gliomas during Anti-Angiogenic Therapy and Its Impact on Imageable Tumor. Front Oncol 2013;3:66. [PMID: 23577324 DOI: 10.3389/fonc.2013.00066] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
87 Liu G, Jeraj R, Vanderhoek M, Perlman S, Kolesar J, Harrison M, Simoncic U, Eickhoff J, Carmichael L, Chao B, Marnocha R, Ivy P, Wilding G. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res 2011;17:7634-44. [PMID: 22038997 DOI: 10.1158/1078-0432.CCR-11-1677] [Cited by in Crossref: 48] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
88 Yin JH, Zhu XY, Shi WD, Liu LM. Huachansu injection inhibits metastasis of pancreatic cancer in mice model of human tumor xenograft. BMC Complement Altern Med 2014;14:483. [PMID: 25496480 DOI: 10.1186/1472-6882-14-483] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
89 Rossi G, Mengoli MC, Cavazza A, Nicoli D, Barbareschi M, Cantaloni C, Papotti M, Tironi A, Graziano P, Paci M, Stefani A, Migaldi M, Sartori G, Pelosi G. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Virchows Arch. 2014;464:61-68. [PMID: 24221342 DOI: 10.1007/s00428-013-1501-6] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 7.1] [Reference Citation Analysis]
90 Seto T, Yamanaka T, Nakano M, Ota M, Maruyama R, Okamoto T, Wataya H, Uematsu K, Seki N, Eguchi K, Semba H, Ichinose Y. Tegafur-uracil plus gemcitabine combination chemotherapy in patients with advanced non-small cell lung cancer previously treated with platinum. J Thorac Oncol 2008;3:637-42. [PMID: 18520804 DOI: 10.1097/JTO.0b013e318174e070] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
91 Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, Nawaz S. Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer 2007;97:391-7. [PMID: 17609662 DOI: 10.1038/sj.bjc.6603875] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 3.2] [Reference Citation Analysis]
92 O'Kane GM, Leighl NB. Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. Transl Lung Cancer Res 2016;5:628-36. [PMID: 28149757 DOI: 10.21037/tlcr.2016.09.05] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
93 Narayanan S, Srinivas S. Incorporating VEGF-targeted therapy in advanced urothelial cancer. Ther Adv Med Oncol 2017;9:33-45. [PMID: 28203296 DOI: 10.1177/1758834016667179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
94 Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards BK. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100:1672-94. [PMID: 19033571 DOI: 10.1093/jnci/djn389] [Cited by in Crossref: 621] [Cited by in F6Publishing: 682] [Article Influence: 44.4] [Reference Citation Analysis]
95 Ramakrishna R, Rostomily R. Seed, soil, and beyond: The basic biology of brain metastasis. Surg Neurol Int 2013;4:S256-64. [PMID: 23717797 DOI: 10.4103/2152-7806.111303] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
96 De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI, Lassman AB. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 2010;100:443-7. [PMID: 20440540 DOI: 10.1007/s11060-010-0200-2] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
97 Spaans JN, Goss GD. Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future. Front Oncol 2014;4:233. [PMID: 25221748 DOI: 10.3389/fonc.2014.00233] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
98 Schellhaas E, Loddenkemper C, Schmittel A, Buhr HJ, Pohlen U. Bowel perforation in non-small cell lung cancer after bevacizumab therapy. Invest New Drugs. 2009;27:184-187. [PMID: 18665327 DOI: 10.1007/s10637-008-9162-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
99 Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 2008;10:355-60. [PMID: 18436627 DOI: 10.1215/15228517-2008-009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
100 Areses Manrique MC, Mosquera Martínez J, García González J, Afonso Afonso FJ, Lázaro Quintela M, Fernández Núñez N, Azpitarte Raposeiras C, Amenedo Gancedo M, Santomé Couto L, García Campelo MR, Muñoz Iglesias J, Cortegoso Mosquera A, Vilchez Simo R, Casal Rubio J, Campos Balea B, Carou Frieiro I, Alonso-Jaudenes Curbera G, Anido Herranz U, García Mata J, Fírvida Pérez JL. Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. Transl Lung Cancer Res 2018;7:404-15. [PMID: 30050778 DOI: 10.21037/tlcr.2018.04.03] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
101 Yagi K, Mitstui M, Zamami Y, Niimura T, Izawa-Ishizawa Y, Goda M, Chuma M, Fukunaga K, Shibata T, Ishida S, Sakurada T, Okada N, Hamano H, Horinouchi Y, Ikeda Y, Yanagawa H, Ishizawa K. Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect. Cancer Med 2021;10:164-72. [PMID: 33231381 DOI: 10.1002/cam4.3587] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 Yamamoto N, Fujiwara Y, Tamura K, Kondo S, Iwasa S, Tanabe Y, Horiike A, Yanagitani N, Kitazono S, Inatani M, Tanaka J, Nishio M. Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer. Invest New Drugs 2017;35:37-46. [PMID: 27565810 DOI: 10.1007/s10637-016-0382-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
103 Tocchetti CG, Cadeddu C, Di Lisi D, Femminò S, Madonna R, Mele D, Monte I, Novo G, Penna C, Pepe A, Spallarossa P, Varricchi G, Zito C, Pagliaro P, Mercuro G. From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. Antioxid Redox Signal 2019;30:2110-53. [PMID: 28398124 DOI: 10.1089/ars.2016.6930] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 10.4] [Reference Citation Analysis]
104 Svaton M, Blazek J, Krakorova G, Buresova M, Teufelova Z, Vodicka J, Hurdalkova K, Barinova M, Pesek M. Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy. J Cancer 2021;12:5753-9. [PMID: 34475989 DOI: 10.7150/jca.58851] [Reference Citation Analysis]
105 Perdrizet K, Leighl NB. The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. Curr Treat Options Oncol 2019;20:21. [PMID: 30778772 DOI: 10.1007/s11864-019-0617-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
106 Gubens MA, Chuang JC, Akerley W, Langer CJ, Clément-Duchêne C, San Pedro-Salcedo M, Colevas AD, Dragnev K, Socinski MA, Wakelee HA. A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. J Thorac Dis 2018;10:219-27. [PMID: 29600052 DOI: 10.21037/jtd.2017.12.30] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387:2008-2016. [PMID: 26969090 DOI: 10.1016/s0140-6736(16)00559-6] [Cited by in Crossref: 342] [Cited by in F6Publishing: 156] [Article Influence: 57.0] [Reference Citation Analysis]
108 Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan BK. A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. Biomedicine (Taipei). 2017;7:23. [PMID: 29130448 DOI: 10.1051/bmdcn/2017070423] [Cited by in Crossref: 150] [Cited by in F6Publishing: 131] [Article Influence: 30.0] [Reference Citation Analysis]
109 Reinmuth N, Bryl M, Bondarenko I, Syrigos K, Vladimirov V, Zereu M, Bair AH, Hilton F, Liau K, Kasahara K. PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study. BioDrugs 2019;33:555-70. [PMID: 31338773 DOI: 10.1007/s40259-019-00363-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
110 Goey AK, Figg WD. Potential novel role of bevacizumab in glioblastoma and cervical cancer. Cancer Biol Ther 2014;15:1296-8. [PMID: 25046485 DOI: 10.4161/cbt.29926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
111 Bratova M, Karlinova B, Skrickova J, Pesek M, Kolek V, Koubkova L, Hrnciarik M, Krejci J, Barinova M, Havel L, Grygarkova I, Brat K. Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry. In Vivo 2020;34:369-79. [PMID: 31882501 DOI: 10.21873/invivo.11783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
112 White MN, Piper-Vallillo AJ, Gardner RM, Cunanan K, Neal JW, Das M, Padda SK, Ramchandran K, Chen TT, Sequist LV, Piotrowska Z, Wakelee HA. Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clin Lung Cancer 2021:S1525-7304(21)00278-3. [PMID: 34887193 DOI: 10.1016/j.cllc.2021.11.001] [Reference Citation Analysis]
113 Wang J, Wang B, Chu H, Yao Y. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Onco Targets Ther 2016;9:3711-26. [PMID: 27382309 DOI: 10.2147/OTT.S106399] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
114 Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34:2969-2979. [PMID: 27354481 DOI: 10.1200/jco.2016.66.9861] [Cited by in Crossref: 258] [Cited by in F6Publishing: 161] [Article Influence: 43.0] [Reference Citation Analysis]
115 Barlési F. [Targeted therapies. New hopes, new challenges]. Rev Mal Respir 2008;25:661-2. [PMID: 18772823 DOI: 10.1016/s0761-8425(08)73795-1] [Reference Citation Analysis]
116 Gerber DE, Swanson P, Lopez-Chavez A, Wong L, Dowlati A, Pennell NA, Cronier DM, Qin A, Ilaria R Jr, Cosaert J, Shahir A, Baggstrom MQ. Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. Lung Cancer 2017;111:108-15. [PMID: 28838379 DOI: 10.1016/j.lungcan.2017.07.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
117 Laine AM, Pompos A, Timmerman R, Jiang S, Story MD, Pistenmaa D, Choy H. The Role of Hypofractionated Radiation Therapy with Photons, Protons, and Heavy Ions for Treating Extracranial Lesions. Front Oncol 2015;5:302. [PMID: 26793619 DOI: 10.3389/fonc.2015.00302] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
118 Cheng H, Xu X, Costa DB, Powell CA, Halmos B. Molecular testing in lung cancer: the time is now. Curr Oncol Rep 2010;12:335-48. [PMID: 20623207 DOI: 10.1007/s11912-010-0118-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
119 Folch E, Costa DB, Wright J, VanderLaan PA. Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. Transl Lung Cancer Res 2015;4:392-403. [PMID: 26380180 DOI: 10.3978/j.issn.2218-6751.2015.08.02] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
120 Trukhin D, Poddubskaya E, Andric Z, Makharadze T, Bellala RS, Charoentum C, Yañez Ruiz EP, Fulop A, Hyder Ali IA, Syrigos K, Katgi N, Lopez Chuken YA, Rumyana I, Reyes-Igama J, Costamilan RC, Del Campo García A, Florez A, Paravisini A, Millan S; STELLA Investigators. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA). BioDrugs 2021;35:429-44. [PMID: 33914256 DOI: 10.1007/s40259-021-00483-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
121 Loganathan S, Kanteti R, Siddiqui SS, El-Hashani E, Tretiakova M, Vigneswaran H, Cervantes G, Natarajan V, Husain AN, Vokes EE, Kindler HL, Salgia R. Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism. J Carcinog 2011;10:4. [PMID: 21383961 DOI: 10.4103/1477-3163.77274] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
122 Spicer J, Irshad S, Ang JE, Enting D, Kristeleit R, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2017;79:17-27. [PMID: 27872953 DOI: 10.1007/s00280-016-3189-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
123 Murakami M, Zhao S, Zhao Y, Chowdhury NF, Yu W, Nishijima K, Takiguchi M, Tamaki N, Kuge Y. Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. Int J Oncol. 2012;41:1593-1600. [PMID: 22965141 DOI: 10.3892/ijo.2012.1624] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
124 Pan F, Tian J, Zhang X, Zhang Y, Pan Y. Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation. J Cancer Res Clin Oncol 2011;137:1397-408. [PMID: 21796416 DOI: 10.1007/s00432-011-1009-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
125 Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 2015;121:1025-31. [PMID: 25417775 DOI: 10.1002/cncr.29169] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
126 Sakakibara-Konishi J, Oizumi S, Kikuchi J, Kikuchi E, Mizugaki H, Kinoshita I, Dosaka-Akita H, Nishimura M. Expression of Bim, Noxa, and Puma in non-small cell lung cancer. BMC Cancer 2012;12:286. [PMID: 22788963 DOI: 10.1186/1471-2407-12-286] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
127 Aya F, Benegas M, Viñolas N, Reyes R, Vollmer I, Arcocha A, Sánchez M, Reguart N. A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC. Cancers (Basel) 2021;13:5566. [PMID: 34771728 DOI: 10.3390/cancers13215566] [Reference Citation Analysis]
128 Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther 2021;14:3037-49. [PMID: 33994796 DOI: 10.2147/OTT.S291801] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
129 Chen J, Lu Y, Zheng Y. Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 2015;9:4751-60. [PMID: 26316712 DOI: 10.2147/DDDT.S87258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
130 Khan H, Alam W, Alsharif KF, Aschner M, Pervez S, Saso L. Alkaloids and Colon Cancer: Molecular Mechanisms and Therapeutic Implications for Cell Cycle Arrest. Molecules 2022;27:920. [DOI: 10.3390/molecules27030920] [Reference Citation Analysis]
131 Janku F, Wheler JJ, Hong DS, Kurzrock R. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. Target Oncol 2013;8:183-8. [PMID: 23400451 DOI: 10.1007/s11523-013-0266-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
132 Yu XW, Wu TY, Yi X, Ren WP, Zhou ZB, Sun YQ, Zhang CQ. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. Tumour Biol 2014;35:155-60. [PMID: 23907576 DOI: 10.1007/s13277-013-1019-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
133 Fan C, Zhang J, Liu Z, He M, Kang T, Du T, Song Y, Fan Y, Xu J. Prognostic role of microvessel density in patients with glioma. Medicine (Baltimore) 2019;98:e14695. [PMID: 30817605 DOI: 10.1097/MD.0000000000014695] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Togashi Y, Kim YH, Masago K, Tamai K, Sakamori Y, Mio T, Mishima M. Pulmonary embolism due to internal jugular vein thrombosis in a patient with non-small cell lung cancer receiving bevacizumab. Int J Clin Oncol 2011;16:444-6. [PMID: 21116671 DOI: 10.1007/s10147-010-0148-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
135 Schulze AB, Evers G, Kerkhoff A, Mohr M, Schliemann C, Berdel WE, Schmidt LH. Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. Cancers (Basel) 2019;11:E690. [PMID: 31108964 DOI: 10.3390/cancers11050690] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
136 Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, García-Campelo R, García Y, Guirado M, Provencio M. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clin Transl Oncol 2019;21:3-17. [PMID: 30446985 DOI: 10.1007/s12094-018-1978-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis]
137 Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol 2019;24:731-70. [PMID: 31049758 DOI: 10.1007/s10147-019-01431-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
138 Fontana E, Sclafani F, Cunningham D. Anti-angiogenic therapies for advanced esophago-gastric cancer. Indian J Med Paediatr Oncol 2014;35:253-62. [PMID: 25538401 DOI: 10.4103/0971-5851.144985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
139 Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep. 2012;14:277-284. [PMID: 22532266 DOI: 10.1007/s11912-012-0238-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
140 Blumenthal GM, Karuri SW, Zhang H, Zhang L, Khozin S, Kazandjian D, Tang S, Sridhara R, Keegan P, Pazdur R. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol 2015;33:1008-14. [PMID: 25667291 DOI: 10.1200/JCO.2014.59.0489] [Cited by in Crossref: 116] [Cited by in F6Publishing: 62] [Article Influence: 16.6] [Reference Citation Analysis]
141 Liang H, Wang M. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. Cancer Manag Res 2019;11:7707-19. [PMID: 31616186 DOI: 10.2147/CMAR.S212238] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
142 Rossi A, Maione P, Ferrara C, Del Gaizo F, Guerriero C, Nicolella D, Palazzolo G, Falanga M, Colantuoni G, Gridelli C. New angiogenic agents and non-small cell lung cancer: current results and future development. Targ Oncol 2007;2:211-23. [DOI: 10.1007/s11523-007-0060-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
143 O'Connor JP, Carano RA, Clamp AR, Ross J, Ho CC, Jackson A, Parker GJ, Rose CJ, Peale FV, Friesenhahn M, Mitchell CL, Watson Y, Roberts C, Hope L, Cheung S, Reslan HB, Go MA, Pacheco GJ, Wu X, Cao TC, Ross S, Buonaccorsi GA, Davies K, Hasan J, Thornton P, del Puerto O, Ferrara N, van Bruggen N, Jayson GC. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 2009;15:6674-82. [PMID: 19861458 DOI: 10.1158/1078-0432.CCR-09-0731] [Cited by in Crossref: 118] [Cited by in F6Publishing: 65] [Article Influence: 9.1] [Reference Citation Analysis]
144 Di Salvatore M, Lo Giudice L, Rossi E, Santonocito C, Nazzicone G, Rodriquenz MG, Cappuccio S, Inno A, Fuso P, Orlandi A, Strippoli A, Capoluongo E, Astone A, Cassano A, Barone C. Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis. Clin Transl Oncol 2016;18:40-6. [PMID: 26141413 DOI: 10.1007/s12094-015-1334-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
145 DI C, Zhao Y. Multiple drug resistance due to resistance to stem cells and stem cell treatment progress in cancer (Review). Exp Ther Med. 2015;9:289-293. [PMID: 25574188 DOI: 10.3892/etm.2014.2141] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
146 Qi WX, Shen Z, Tang LN, Yao Y. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol 2014;78:748-62. [PMID: 24661224 DOI: 10.1111/bcp.12387] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 8.3] [Reference Citation Analysis]
147 Serrano Solares S, Isla Casado D, Vidal Losada MJ, Tobeña Puyal M, Ferrer Pérez AI, Pajares I. Dramatic complete response in patient with lung adenocarcinoma. Clin Transl Oncol 2009;11:851-3. [PMID: 20045793 DOI: 10.1007/s12094-009-0455-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
148 Santos ES, Turquie MH, Castillero L, Raez LE, Rolfo C. Making Sense of Immunotherapy in Lung Cancer: What the Pulmonologist Needs to Know? Curr Pulmonol Rep 2018;7:42-8. [DOI: 10.1007/s13665-018-0200-9] [Reference Citation Analysis]
149 Tiefenbacher A, Pirker R. Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives. Memo 2018;11:112-5. [PMID: 29983826 DOI: 10.1007/s12254-018-0408-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
150 Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010;10:186. [PMID: 20459695 DOI: 10.1186/1471-2407-10-186] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
151 Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara DR. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:56-62. [PMID: 19933908 DOI: 10.1200/jco.2009.24.9094] [Cited by in Crossref: 196] [Cited by in F6Publishing: 108] [Article Influence: 15.1] [Reference Citation Analysis]
152 Rapisarda A, Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 2012;9:378-90. [PMID: 22525710 DOI: 10.1038/nrclinonc.2012.64] [Cited by in Crossref: 115] [Cited by in F6Publishing: 102] [Article Influence: 11.5] [Reference Citation Analysis]
153 Boige V, Malka D, Bourredjem A, Dromain C, Baey C, Jacques N, Pignon JP, Vimond N, Bouvet-Forteau N, De Baere T, Ducreux M, Farace F. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist. 2012;17:1063-1072. [PMID: 22707516 DOI: 10.1634/theoncologist.2011-0465] [Cited by in Crossref: 66] [Cited by in F6Publishing: 54] [Article Influence: 6.6] [Reference Citation Analysis]
154 Lazarus M, Amundson S, Belani R. An Association between Bevacizumab and Recurrent Posterior Reversible Encephalopathy Syndrome in a Patient Presenting with Deep Vein Thrombosis: A Case Report and Review of the Literature. Case Rep Oncol Med 2012;2012:819546. [PMID: 23243534 DOI: 10.1155/2012/819546] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
155 Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009;27:1405-12. [PMID: 19224857 DOI: 10.1200/JCO.2008.16.2412] [Cited by in Crossref: 108] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
156 Ni X, Han JQ, Ye X, Wei ZG. Percutaneous CT-guided microwave ablation as maintenance after first-line treatment for patients with advanced NSCLC. Onco Targets Ther 2015;8:3227-35. [PMID: 26604789 DOI: 10.2147/OTT.S90528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
157 Kim DY, Lee DH, Jang SJ, Kim SW, Suh C, Lee JS. Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment. Cancer Res Treat 2011;43:212-6. [PMID: 22247705 DOI: 10.4143/crt.2011.43.4.212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
158 van Mackelenbergh MG, Stroes CI, Spijker R, van Eijck CHJ, Wilmink JW, Bijlsma MF, van Laarhoven HWM. Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;11. [PMID: 31035512 DOI: 10.3390/cancers11050588] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
159 Chow LQ, Smith DC, Tan AR, Denlinger CS, Wang D, Shepard DR, Chaudhary A, Lin Y, Gao L. Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors. Cancer Chemother Pharmacol 2016;78:433-41. [PMID: 27379498 DOI: 10.1007/s00280-016-3098-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
160 Masuda D, Masuda R, Matsuzaki T, Imamura N, Aruga N, Tanaka M, Inokuchi S, Kijima H, Iwazaki M. Ki-67 labeling index affects tumor infiltration patterns of lung squamous cell carcinoma. Mol Med Rep 2015;12:7303-9. [PMID: 26459875 DOI: 10.3892/mmr.2015.4354] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
161 Tolnay E, Ghimessy ÁK, Juhász E, Sztancsik Z, Losonczy G, Dombi P, Vennes Z, Helf L, Csada E, Sárosi V. The efficacy and safety of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer: Final results of AVALANCHE, an observational cohort study. Oncol Lett 2019;17:1750-60. [PMID: 30675234 DOI: 10.3892/ol.2018.9766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
162 Meyer G, Belmont L. [Cancer and venous thromboembolism]. Rev Mal Respir 2011;28:443-52. [PMID: 21549900 DOI: 10.1016/j.rmr.2011.02.007] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
163 Gadgeel SM, Cote ML, Schwartz AG, Matherly LH, Wozniak A, Bepler G. Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resist Updat 2010;13:196-204. [PMID: 21051275 DOI: 10.1016/j.drup.2010.10.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
164 Gentzler RD, Patel JD. Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications. Ther Adv Med Oncol 2014;6:4-15. [PMID: 24381656 DOI: 10.1177/1758834013510589] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
165 Sacco PC, Maione P, Rossi A, Bareschino MA, Schettino C, Guida C, Elmo M, Ambrosio R, Barbato V, Zeppa R, Palazzolo G, Gridelli C. Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. Target Oncol 2011;6:171-80. [PMID: 21409591 DOI: 10.1007/s11523-011-0169-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
166 Sun L, Xiong Z, Han C. [Research Advances of Pan-negative Type of Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2018;21:129-38. [PMID: 29526181 DOI: 10.3779/j.issn.1009-3419.2018.02.07] [Reference Citation Analysis]
167 Chow LQ, Blais N, Jonker DJ, Laurie SA, Diab SG, Canil C, McWilliam M, Thall A, Ruiz-Garcia A, Zhang K, Tye L, Chao RC, Camidge DR. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Cancer Chemother Pharmacol 2012;69:709-22. [PMID: 21989766 DOI: 10.1007/s00280-011-1755-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
168 Chino H, Amano Y, Yamauchi Y, Matsuda J, Takeda N, Tanaka G, Takai D, Nagase T. Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer. J Thorac Dis 2016;8:2646-50. [PMID: 27747019 DOI: 10.21037/jtd.2016.08.96] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
169 Zhou J, Gao B. [The status and prospects of treatment protocols for elderly patients with non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2011;14:598-605. [PMID: 21762630 DOI: 10.3779/j.issn.1009-3419.2011.07.07] [Reference Citation Analysis]
170 Qi WX, Shen Z, Tang LN, Yao Y. The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials. Tumour Biol. 2014;35:7675-7683. [PMID: 24801910 DOI: 10.1007/s13277-014-2037-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
171 McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99:2006-12. [PMID: 19078952 DOI: 10.1038/sj.bjc.6604808] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 6.9] [Reference Citation Analysis]
172 Ohlmann CH, Markert E, Gerharz M, Pfister D, Dienes HP, Engelmann U, Heidenreich A. [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer]. Urologe A 2008;47:1218-23. [PMID: 18679646 DOI: 10.1007/s00120-008-1839-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
173 Nishino M, Cryer SK, Okajima Y, Sholl LM, Hatabu H, Rabin MS, Jackman DM, Johnson BE. Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab. Cancer Imaging 2012;12:225-35. [PMID: 22743083 DOI: 10.1102/1470-7330.2012.0027] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
174 Chen RL, Zhou JX, Cao Y, Sun LL, Su S, Deng XJ, Lin JT, Xiao ZW, Chen ZZ, Wang SY, Lin LZ. Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival. Front Immunol 2020;11:1933. [PMID: 33072067 DOI: 10.3389/fimmu.2020.01933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
175 Doebele RC, Conkling P, Traynor AM, Otterson GA, Zhao Y, Wind S, Stopfer P, Kaiser R, Camidge DR. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2012;23:2094-102. [PMID: 22345119 DOI: 10.1093/annonc/mdr596] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
176 Kikuchi H, Sakakibara-Konishi J, Furuta M, Kikuchi E, Kikuchi J, Oizumi S, Hida Y, Kaga K, Kinoshita I, Dosaka-Akita H, Nishimura M. Numb has distinct function in lung adenocarcinoma and squamous cell carcinoma. Oncotarget. 2018;9:29379-29391. [PMID: 30034624 DOI: 10.18632/oncotarget.25585] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
177 Brooks GA, Li L, Sharma DB, Weeks JC, Hassett MJ, Yabroff KR, Schrag D. Regional variation in spending and survival for older adults with advanced cancer. J Natl Cancer Inst 2013;105:634-42. [PMID: 23482657 DOI: 10.1093/jnci/djt025] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
178 Schilsky RL, Geary D, Skoog L, Desai AA, Valickas J, Chen B, Masson E, Laurent D, Pendowski C, Vokes EE, Ratain MJ. Phase I and pharmacokinetic study of vatalanib plus capecitabine in patients with advanced cancer. Targ Oncol 2008;3:3-11. [DOI: 10.1007/s11523-007-0070-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
179 Cedrych I, Kruczała MA, Walasek T, Jakubowicz J, Blecharz P, Reinfuss M. Systemic treatment of non-small cell lung cancer brain metastases. Contemp Oncol (Pozn) 2016;20:352-7. [PMID: 28373815 DOI: 10.5114/wo.2016.64593] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
180 Digklia A, Voutsadakis IA. Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status. World J Exp Med 2014; 4(4): 58-67 [PMID: 25414818 DOI: 10.5493/wjem.v4.i4.58] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
181 Zarei Mahmudabadi A, Masoomi Karimi M, Bahabadi M, Bagheri Hoseinabadi Z, JafariSani M, Ahmadi R. Inhibition of AGS Cancer Cell Proliferation following siRNA-Mediated Downregulation of VEGFR2. Cell J 2016;18:381-8. [PMID: 27602320 DOI: 10.22074/cellj.2016.4566] [Reference Citation Analysis]
182 Formisano L, Jansen VM, Marciano R, Bianco R. From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer. Anticancer Agents Med Chem 2018;18:1235-40. [PMID: 28901258 DOI: 10.2174/1871520617666170912123416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
183 Kosty MP, Wozniak AJ, Jahanzeb M, Leon L, Fish S, Hazard SJ, Lynch TJ Jr. Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study. Target Oncol 2015;10:509-16. [PMID: 25559289 DOI: 10.1007/s11523-014-0355-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
184 Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol 2014;7:70. [PMID: 25277503 DOI: 10.1186/s13045-014-0070-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 10.5] [Reference Citation Analysis]
185 Yu Z, Cai X, Xu Z, He Z, Lai J, Wang W, Zhang J, Kong W, Huang X, Chen Y, Shi Y, Shi X, Zhao Z, Ni M, Lin X, Chen S, Wu X, Chen W, Song Z, Huang C. Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial. Oncologist 2020;25:e1640-9. [PMID: 32533785 DOI: 10.1634/theoncologist.2020-0519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
186 Domvri K, Zarogoulidis P, Darwiche K, Browning RF, Li Q, Turner JF, Kioumis I, Spyratos D, Porpodis K, Papaiwannou A, Tsiouda T, Freitag L, Zarogoulidis K. Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. J Cancer 2013;4:736-54. [PMID: 24312144 DOI: 10.7150/jca.7734] [Cited by in Crossref: 32] [Cited by in F6Publishing: 52] [Article Influence: 3.6] [Reference Citation Analysis]
187 Li X, Huang J, Qiu Y, Zhang Q, Yang S, Wu K, Wang J, Wang L, Ye J, Ma S, Xia B, Chen X. Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study. Front Pharmacol 2021;12:649222. [PMID: 34025415 DOI: 10.3389/fphar.2021.649222] [Reference Citation Analysis]
188 Hirsh V. Review of the treatment of metastatic non small cell lung carcinoma: A practical approach. World J Clin Oncol 2011; 2(6): 262-271 [PMID: 21773076 DOI: 10.5306/wjco.v2.i6.262] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
189 Eklund L, Bry M, Alitalo K. Mouse models for studying angiogenesis and lymphangiogenesis in cancer. Mol Oncol 2013;7:259-82. [PMID: 23522958 DOI: 10.1016/j.molonc.2013.02.007] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 8.4] [Reference Citation Analysis]
190 Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R, Ferrara N. Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci U S A. 2007;104:10625-10630. [PMID: 17553957 DOI: 10.1073/pnas.0704213104] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
191 Liu KJ, Guan ZZ, Liang Y, Yang XQ, Peng J, Huang H, Shao QX, Wang MZ, Zhu YZ, Wu CP, Wang SB, Xiong JP, Bai YX, Yu SY, Zhang Y, Hu XH, Feng JF, Wu SX, Jiao SC, Zhou CC, Wang J, Wu HY. A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers. Arch Med Sci 2014;10:717-24. [PMID: 25276156 DOI: 10.5114/aoms.2014.44862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
192 Bottos A, Bardelli A. Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy? Cell Mol Life Sci 2013;70:4131-40. [PMID: 23685900 DOI: 10.1007/s00018-013-1331-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
193 Ramnath N, Daignault-Newton S, Dy GK, Muindi JR, Adjei A, Elingrod VL, Kalemkerian GP, Cease KB, Stella PJ, Brenner DE, Troeschel S, Johnson CS, Trump DL. A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2013;71:1173-82. [PMID: 23435876 DOI: 10.1007/s00280-013-2109-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
194 Miura S, Maemondo M, Iwashima A, Harada T, Sugawara S, Kobayashi K, Inoue A, Nakagawa T, Takiguchi Y, Watanabe H, Ishida T, Terada M, Kagamu H, Gemma A, Yoshizawa H. A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016). Invest New Drugs 2017;35:227-34. [PMID: 28150074 DOI: 10.1007/s10637-017-0436-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
195 Backen A, Renehan AG, Clamp AR, Berzuini C, Zhou C, Oza A, Bannoo S, Scherer SJ, Banks RE, Dive C, Jayson GC. The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. Clin Cancer Res 2014;20:4549-58. [PMID: 24947924 DOI: 10.1158/1078-0432.CCR-13-3248] [Reference Citation Analysis]
196 Shin SJ, Jeung HC, Ahn JB, Rha SY, Roh JK, Park KS, Kim DH, Kim C, Chung HC. A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Invest New Drugs 2010;28:650-8. [PMID: 19585083 DOI: 10.1007/s10637-009-9287-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
197 Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol. 2010;28:4747-4754. [PMID: 20921467 DOI: 10.1200/jco.2009.27.9356] [Cited by in Crossref: 48] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
198 Suzuki H, Hirashima T, Kobayashi M, Okamoto N, Matsuura Y, Tamiya M, Morishita N, Okafuji K, Shiroyama T, Morimura O, Morita S, Kawase I. Carboplatin plus paclitaxel in combination with bevacizumab for the treatment of adenocarcinoma with interstitial lung diseases. Mol Clin Oncol 2013;1:480-2. [PMID: 24649195 DOI: 10.3892/mco.2013.82] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
199 Jun N, Hanping W, Xiaoyan S, Yan X, Mengzhao W, Xiaotong Z, Li Z. Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study. Thorac Cancer 2020;11:1869-75. [PMID: 32406994 DOI: 10.1111/1759-7714.13469] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
200 Shen H, Zhu F, Liu J, Xu T, Pei D, Wang R, Qian Y, Li Q, Wang L, Shi Z, Zheng J, Chen Q, Jiang B, Shu Y. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. PLoS One 2014;9:e103305. [PMID: 25058005 DOI: 10.1371/journal.pone.0103305] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 7.6] [Reference Citation Analysis]
201 Xiao J, Xu X, Li X, Li Y, Liu G, Tan H, Shen H, Shi H, Cheng D. Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer. Molecules 2016;21:E1308. [PMID: 27706035 DOI: 10.3390/molecules21101308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
202 Zhou CC, Bai CX, Guan ZZ, Jiang GL, Shi YK, Wang MZ, Wu YL, Zhang YP, Zhu YZ. Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study. Clin Transl Oncol 2014;16:463-8. [PMID: 24002945 DOI: 10.1007/s12094-013-1102-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
203 Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, Toschi L, Incarbone M, Cavina R, Terracciano L, Roncalli M, Alloisio M, Varella-Garcia M, Franklin WA, Santoro A. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol 2010;21:562-7. [PMID: 19767315 DOI: 10.1093/annonc/mdp357] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 4.8] [Reference Citation Analysis]
204 Tan AR, Dowlati A, Jones SF, Infante JR, Nishioka J, Fang L, Hodge JP, Gainer SD, Arumugham T, Suttle AB, Dar MM, Lager JJ, Burris HA 3rd. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 2010;15:1253-61. [PMID: 21147873 DOI: 10.1634/theoncologist.2010-0095] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
205 Siegal T. Which drug or drug delivery system can change clinical practice for brain tumor therapy? Neuro Oncol 2013;15:656-69. [PMID: 23502426 DOI: 10.1093/neuonc/not016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
206 Yamaguchi K, Masuda T, Fujitaka K, Miwata K, Sakamoto S, Horimasu Y, Hamai K, Miyamoto S, Nakashima T, Okamoto Y, Iwamoto H, Ishikawa N, Miyata Y, Okada M, Hamada H, Hattori N. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study. In Vivo 2018;32:1155-60. [PMID: 30150438 DOI: 10.21873/invivo.11358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
207 Yu KH, Zhang C, Berry GJ, Altman RB, Ré C, Rubin DL, Snyder M. Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features. Nat Commun 2016;7:12474. [PMID: 27527408 DOI: 10.1038/ncomms12474] [Cited by in Crossref: 362] [Cited by in F6Publishing: 285] [Article Influence: 60.3] [Reference Citation Analysis]
208 Chirieac LR, Dacic S. Targeted Therapies in Lung Cancer. Surg Pathol Clin 2010;3:71-82. [PMID: 20680095 DOI: 10.1016/j.path.2010.04.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
209 Horinouchi H. Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer. Transl Lung Cancer Res 2016;5:78-81. [PMID: 26958495 DOI: 10.3978/j.issn.2218-6751.2015.06.08] [Reference Citation Analysis]
210 Monk BJ, Lammers PE, Cartwright T, Jacobs I. Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey. Pharmaceuticals (Basel) 2017;10:E19. [PMID: 28134851 DOI: 10.3390/ph10010019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
211 Kaiser K, Beaumont JL, Webster K, Yount SE, Wagner LI, Kuzel TM, Cella D. Development and validation of the functional assessment of cancer therapy-antiangiogenesis subscale. Cancer Med 2015;4:690-8. [PMID: 25619758 DOI: 10.1002/cam4.385] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
212 Sato T, Soejima K, Fujisawa D, Takeuchi M, Arai D, Nakachi I, Naoki K, Kawada I, Yasuda H, Ishioka K, Nukaga S, Kobayashi K, Masaki K, Inoue T, Hikima K, Nakamura M, Ohgino K, Oyamada Y, Funatsu Y, Terashima T, Miyao N, Sayama K, Saito F, Sakamaki F, Betsuyaku T. Prognostic Understanding at Diagnosis and Associated Factors in Patients with Advanced Lung Cancer and Their Caregivers. Oncologist 2018;23:1218-29. [PMID: 30120158 DOI: 10.1634/theoncologist.2017-0329] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
213 Fontenot E, Rossi E, Mumper R, Snyder S, Siamakpour-Reihani S, Ma P, Hilliard E, Bone B, Ketelsen D, Santos C, Patterson C, Klauber-DeMore N. A novel monoclonal antibody to secreted frizzled-related protein 2 inhibits tumor growth. Mol Cancer Ther 2013;12:685-95. [PMID: 23604067 DOI: 10.1158/1535-7163.MCT-12-1066] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
214 Eisenbeis AM, Grau SJ. Monoclonal antibodies and Fc fragments for treating solid tumors. Biologics 2012;6:13-20. [PMID: 22291463 DOI: 10.2147/BTT.S19955] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
215 Johnpulle RA, Johnson DB, Sosman JA. Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. Curr Oncol Rep 2016;18:6. [PMID: 26743513 DOI: 10.1007/s11912-015-0485-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
216 Verwer EE, Boellaard R, Veldt AAVD. Positron emission tomography to assess hypoxia and perfusion in lung cancer. World J Clin Oncol 2014; 5(5): 824-844 [PMID: 25493221 DOI: 10.5306/wjco.v5.i5.824] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
217 Liu KJ, Ding LY, Wu HY. Bevacizumab in combination with anticancer drugs for previously treated advanced non-small cell lung cancer. Tumour Biol 2015;36:1323-7. [PMID: 25731729 DOI: 10.1007/s13277-014-2962-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
218 Lorusso P, Heath EI, McGreivy J, Sun YN, Melara R, Yan L, Malburg L, Ingram M, Wiezorek J, Chen L, Pilat MJ. Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors. Invest New Drugs 2008;26:455-62. [PMID: 18574557 DOI: 10.1007/s10637-008-9144-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
219 Anbalagan M, Ali A, Jones RK, Marsden CG, Sheng M, Carrier L, Bu Y, Hangauer D, Rowan BG. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts. Mol Cancer Ther 2012;11:1936-47. [PMID: 22784709 DOI: 10.1158/1535-7163.MCT-12-0146] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
220 Elster JD, McGuire TF, Lu J, Prochownik EV. Rapid in vitro derivation of endothelium directly from human cancer cells. PLoS One 2013;8:e77675. [PMID: 24130897 DOI: 10.1371/journal.pone.0077675] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
221 Hamilton HK, Rose AE, Christos PJ, Shapiro RL, Berman RS, Mazumdar M, Ma MW, Krich D, Liebes L, Brooks PC, Osman I. Increased shedding of HU177 correlates with worse prognosis in primary melanoma. J Transl Med 2010;8:19. [PMID: 20178639 DOI: 10.1186/1479-5876-8-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
222 Zee YK, Eisen T. Survival from lung cancer in England and Wales up to 2001. Br J Cancer 2008;99 Suppl 1:S43-6. [PMID: 18813257 DOI: 10.1038/sj.bjc.6604584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
223 Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight 2016;1:e87754. [PMID: 27777972 DOI: 10.1172/jci.insight.87754] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
224 Zhang J, Zhou F, Qi H, Ni H, Hu Q, Zhou C, Li Y, Baburina I, Courtney J, Salamone SJ. Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. Br J Clin Pharmacol 2019;85:2292-301. [PMID: 31077432 DOI: 10.1111/bcp.13982] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
225 Fukazawa T, Guo M, Ishida N, Yamatsuji T, Takaoka M, Yokota E, Haisa M, Miyake N, Ikeda T, Okui T, Takigawa N, Maeda Y, Naomoto Y. SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma. Sci Rep 2016;6:20113. [PMID: 26846300 DOI: 10.1038/srep20113] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
226 Zhang J, Zhang W, Huang S, Li H, Li Y, Chen H, Wu W, Zhou W, Wang C, Liao H, Gu L. Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. Exp Ther Med 2012;4:849-58. [PMID: 23226738 DOI: 10.3892/etm.2012.690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
227 Shimada M, Itamochi H, Kigawa J. Nedaplatin: a cisplatin derivative in cancer chemotherapy. Cancer Manag Res 2013;5:67-76. [PMID: 23696716 DOI: 10.2147/CMAR.S35785] [Cited by in Crossref: 58] [Cited by in F6Publishing: 19] [Article Influence: 6.4] [Reference Citation Analysis]
228 Mountzios G. Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era? Transl Lung Cancer Res 2018;7:S179-82. [PMID: 29782560 DOI: 10.21037/tlcr.2018.03.24] [Reference Citation Analysis]
229 Huylebrouck M, Lv S, Duerinck J, Van Binst A, Salmon I, De Greve J, De Witte O, Luce S, Michotte A, D'Haens J, Neyns B. An observational study of the first experience with bevacizumab for the treatment of patients with recurrent high-grade glioma in two belgian university hospitals. J Oncol 2012;2012:801306. [PMID: 22481934 DOI: 10.1155/2012/801306] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
230 Lai XX, Xu RA, Yu-Ping L, Yang H. Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther 2016;9:2421-8. [PMID: 27143937 DOI: 10.2147/OTT.S96156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
231 Watanabe M, Boyer JL, Crystal RG. Genetic delivery of bevacizumab to suppress vascular endothelial growth factor-induced high-permeability pulmonary edema. Hum Gene Ther 2009;20:598-610. [PMID: 19254174 DOI: 10.1089/hum.2008.169] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
232 Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J, Zhang HP, Zhang L, Luo J, Zhang J, Tang L, Su B, Chen G, Zhu G, Gu Y, Xu JF. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep 2016;6:20913. [PMID: 26867973 DOI: 10.1038/srep20913] [Cited by in Crossref: 118] [Cited by in F6Publishing: 142] [Article Influence: 19.7] [Reference Citation Analysis]
233 Ueki A, Okuma T, Hamamoto S, Kageyama K, Murai K, Miki Y. Combination therapy involving radiofrequency ablation and targeted chemotherapy with bevacizumab plus paclitaxel and cisplatin in a rabbit VX2 lung tumor model. BMC Res Notes 2018;11:251. [PMID: 29690935 DOI: 10.1186/s13104-018-3358-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
234 Schneider BJ, Kalemkerian GP, Gadgeel SM, Valdivieso M, Hackstock DM, Chen W, Heilbrun LK, Ruckdeschel JC, Wozniak AJ. Phase II Trial of Dose-dense Pemetrexed, Gemcitabine, and Bevacizumab in Patients With Advanced, Non-Small-cell Lung Cancer. Clin Lung Cancer 2017;18:299-302. [PMID: 28063799 DOI: 10.1016/j.cllc.2016.11.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
235 Zhuang J, Yu Y, Li Z, Lu S. Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis. Oncotarget 2017;8:53675-83. [PMID: 28881841 DOI: 10.18632/oncotarget.15726] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
236 Lee JM, Sarosy GA, Annunziata CM, Azad N, Minasian L, Kotz H, Squires J, Houston N, Kohn EC. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer. 2010;102:495-499. [PMID: 20051952 DOI: 10.1038/sj.bjc.6605514] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
237 Deslypere G, Gullentops D, Wauters E, Vansteenkiste J. Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages? Ther Adv Med Oncol 2018;10:1758835918772810. [PMID: 29774061 DOI: 10.1177/1758835918772810] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
238 Choi SH, Yoo SS, Lee SY, Park JY. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. Arch Pharm Res 2022. [PMID: 35449345 DOI: 10.1007/s12272-022-01382-6] [Reference Citation Analysis]
239 Marti-climent J, Dominguez-prado I, Garcia-velloso M, Boni V, Peñuelas I, Toledo I, Richter J. [18F]fluorothymidine-positron emission tomography in patients with locally advanced breast cancer under bevacizumab treatment: Usefulness of different quantitative methods of tumor proliferation. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2014;33:280-5. [DOI: 10.1016/j.remnie.2014.08.002] [Reference Citation Analysis]
240 Qi WX, Shen Z, Tang LN, Yao Y. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol. 2014;70:893-906. [PMID: 24858820 DOI: 10.1007/s00228-014-1687-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
241 Liu L, Bi N, Wu L, Ding X, Men Y, Zhou W, Li L, Zhang W, Shi S, Song Y, Wang L. MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma. Mol Cancer 2017;16:50. [PMID: 28241836 DOI: 10.1186/s12943-017-0620-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
242 Zhang L, Liu D, Li L, Pu D, Zhou P, Jing Y, Yu H, Wang Y, Zhu Y, He Y, Li Y, Zhao S, Qiu Z, Li W. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients. BMC Cancer 2017;17:96. [PMID: 28152979 DOI: 10.1186/s12885-017-3070-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
243 Brahmer JR, Dahlberg SE, Gray RJ, Schiller JH, Perry MC, Sandler A, Johnson DH. Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. J Thorac Oncol 2011;6:103-8. [PMID: 21079521 DOI: 10.1097/JTO.0b013e3181fa8efd] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
244 Takeda M, Nakagawa K. First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer? Int J Mol Sci 2019;20:E146. [PMID: 30609789 DOI: 10.3390/ijms20010146] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 19.3] [Reference Citation Analysis]
245 Sleeman J, Steeg PS. Cancer metastasis as a therapeutic target. Eur J Cancer 2010;46:1177-80. [PMID: 20307970 DOI: 10.1016/j.ejca.2010.02.039] [Cited by in Crossref: 125] [Cited by in F6Publishing: 122] [Article Influence: 10.4] [Reference Citation Analysis]
246 Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer. 2009;100:1704-1719. [PMID: 19436303 DOI: 10.1038/sj.bjc.6605061] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 5.8] [Reference Citation Analysis]
247 Tanaka M, Ishii H, Azuma K, Saisho C, Matsuo N, Imamura Y, Tokito T, Kinoshita T, Yamada K, Takedatsu H, Mitsuyama K, Hoshino T. Ulcerative colitis in a patient with non-small-cell lung cancer receiving bevacizumab. Invest New Drugs 2015;33:1133-5. [PMID: 26280212 DOI: 10.1007/s10637-015-0279-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
248 Togashi Y, Masago K, Kubo T, Fujimoto D, Sakamori Y, Nagai H, Kim YH, Togashi K, Mishima M. Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma. Med Oncol 2012;29:3169-75. [PMID: 22492281 DOI: 10.1007/s12032-012-0235-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
249 Blanchard P, Besse B, Deutsch E. Bevacizumab et radiothérapie. Revue des Maladies Respiratoires 2008;25:1319-21. [DOI: 10.1016/s0761-8425(08)75095-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
250 Isla D, González-Rojas N, Nieves D, Brosa M, Finnern HW. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clin Transl Oncol 2011;13:460-71. [PMID: 21775273 DOI: 10.1007/s12094-011-0683-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
251 Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 2017; 8(1): 1-20 [PMID: 28246582 DOI: 10.5306/wjco.v8.i1.1] [Cited by in CrossRef: 102] [Cited by in F6Publishing: 95] [Article Influence: 20.4] [Reference Citation Analysis]
252 Clément-Duchêne C, Godbert B, Martinet Y. [Anti-angiogenic agents in the treatment of lung cancer: indications and toxicities]. Rev Mal Respir 2012;29:161-77. [PMID: 22405111 DOI: 10.1016/j.rmr.2011.06.017] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
253 Antonelli G, Libra M, Panebianco V, Russo AE, Vitale FV, Colina P, D'Angelo A, Rossello R, Ferraù F. Molecular-targeted therapy for elderly patients with advanced non-small cell lung cancer. Oncol Lett 2016;11:3-8. [PMID: 26870160 DOI: 10.3892/ol.2015.3901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
254 Roth JA, Goulart BH, Ravelo A, Kolkey H, Ramsey SD. Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities. Oncologist 2017;22:304-10. [PMID: 28242792 DOI: 10.1634/theoncologist.2016-0253] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
255 Bouganim N, Mamo A, Wasserman DW, Batist G, Metrakos P, Chaudhury P, Hassanain M, Kavan P. Bevacizumab-based therapy for colorectal cancer: experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009. Curr Oncol 2013;20:247-51. [PMID: 24155628 DOI: 10.3747/co.20.1370] [Reference Citation Analysis]
256 Cao Y. Future options of anti-angiogenic cancer therapy. Chin J Cancer 2016;35:21. [PMID: 26879126 DOI: 10.1186/s40880-016-0084-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
257 Sun L, Ma JT, Zhang SL, Zou HW, Han CB. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis. Med Oncol 2015;32:473. [PMID: 25603953 DOI: 10.1007/s12032-014-0473-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
258 Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011;22:2616-2624. [PMID: 22071650 DOI: 10.1093/annonc/mdr489] [Cited by in Crossref: 257] [Cited by in F6Publishing: 241] [Article Influence: 23.4] [Reference Citation Analysis]
259 Hwang JE, Lee JH, Park MR, Kim DE, Bae WK, Shim HJ, Cho SH, Chung IJ. Blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in gastric cancer cells. Yonsei Med J 2013;54:374-80. [PMID: 23364970 DOI: 10.3349/ymj.2013.54.2.374] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
260 Bota M, Fischer-Fodor E, Bochiș OV, Cenariu M, Popa G, Blag CL, Tătaru A. Combined effect of propranolol, vincristine and bevacizumab on HUVECs and BJ cells. Exp Ther Med 2019;17:307-15. [PMID: 30651796 DOI: 10.3892/etm.2018.6925] [Reference Citation Analysis]
261 Cortés-Funes H. The role of antiangiogenesis therapy: bevacizumab and beyond. Clin Transl Oncol 2009;11:349-55. [PMID: 19531449 DOI: 10.1007/s12094-009-0368-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
262 Maharaj AS, Walshe TE, Saint-Geniez M, Venkatesha S, Maldonado AE, Himes NC, Matharu KS, Karumanchi SA, D'Amore PA. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med 2008;205:491-501. [PMID: 18268040 DOI: 10.1084/jem.20072041] [Cited by in Crossref: 122] [Cited by in F6Publishing: 106] [Article Influence: 8.7] [Reference Citation Analysis]
263 Tanimura K, Yamada T, Omura A, Shiotsu S, Kataoka N, Takeda T, Taniguchi R, Yamada T, Takeuchi M, Chihara Y, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K. The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study. Front Oncol 2021;11:663612. [PMID: 34123822 DOI: 10.3389/fonc.2021.663612] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
264 Zhou T, Zheng L, Hu Z, Zhang Y, Fang W, Zhao Y, Ge J, Zhao H, Zhang L. The effectiveness of RECIST on survival in patients with NSCLC receiving chemotherapy with or without target agents as first-line treatment. Sci Rep 2015;5:7683. [PMID: 25567662 DOI: 10.1038/srep07683] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
265 Lin JJ, Muzikansky A, Kennedy E, Kuberski H, Stober LL, Wanat AC, Azzoli CG, Lennes I, Sequist LV, Dagogo-Jack I, Shaw AT, Gainor JF. Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study. ESMO Open 2021;7:100342. [PMID: 34896762 DOI: 10.1016/j.esmoop.2021.100342] [Reference Citation Analysis]
266 West H. The evolving role of targeted therapy in early-stage and locally advanced non-small cell lung cancer. Curr Oncol Rep 2011;13:280-9. [PMID: 21633785 DOI: 10.1007/s11912-011-0181-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
267 Tanaka F, Yoneda K. Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC). Surg Today 2016;46:25-37. [PMID: 25925615 DOI: 10.1007/s00595-015-1174-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
268 Sunshine SB, Dallabrida SM, Durand E, Ismail NS, Bazinet L, Birsner AE, Sohn R, Ikeda S, Pu WT, Kulke MH, Javaherian K, Zurakowski D, Folkman JM, Rupnick M. Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc Natl Acad Sci U S A 2012;109:11306-11. [PMID: 22733742 DOI: 10.1073/pnas.1203275109] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
269 Aapro M, Saad F, Costa L. Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. Oncologist 2010;15:1147-58. [PMID: 21051658 DOI: 10.1634/theoncologist.2007-0245] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
270 Zhong R, Ling X, Cao S, Xu J, Zhang B, Zhang X, Wang H, Han B, Zhong H. Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers. ESMO Open 2021;7:100334. [PMID: 34959168 DOI: 10.1016/j.esmoop.2021.100334] [Reference Citation Analysis]
271 Elgamacy MA, Shalaby RA, Elkodsh AT, Kamel AF, Elsayed MS, Abou-El-Ella DA. New inhibitors of VEGFR-2 targeting the extracellular domain dimerization process. Bioinformation 2011;7:52-8. [PMID: 21938205 DOI: 10.6026/97320630007052] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
272 Rangachari D, Costa DB. Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. Transl Cancer Res 2017;6:S151-7. [PMID: 30613479 DOI: 10.21037/tcr.2017.02.28] [Reference Citation Analysis]
273 Tamura T, Kurishima K, Nakazawa K, Ishikawa H, Satoh H, Hizawa N. Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer. Oncol Lett 2015;10:1135-40. [PMID: 26622639 DOI: 10.3892/ol.2015.3350] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
274 Niu G, Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets. 2010;11:1000-1017. [PMID: 20426765 DOI: 10.2174/138945010791591395] [Cited by in Crossref: 188] [Cited by in F6Publishing: 164] [Article Influence: 15.7] [Reference Citation Analysis]
275 d'Onofrio A, Gandolfi A, Rocca A. The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings. Cell Prolif 2009;42:317-29. [PMID: 19438898 DOI: 10.1111/j.1365-2184.2009.00595.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
276 Freidlin B, Korn EL, Gray R. A general inefficacy interim monitoring rule for randomized clinical trials. Clinical Trials 2010;7:197-208. [DOI: 10.1177/1740774510369019] [Cited by in Crossref: 41] [Article Influence: 3.4] [Reference Citation Analysis]
277 He J, Wang Z, Wang Y, Zou T, Li XP, Cao L, Chen J. The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy. Pharmgenomics Pers Med 2021;14:1193-203. [PMID: 34566424 DOI: 10.2147/PGPM.S325788] [Reference Citation Analysis]
278 Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039-2049. [PMID: 18463380 DOI: 10.1056/nejmra0706596] [Cited by in Crossref: 1525] [Cited by in F6Publishing: 799] [Article Influence: 108.9] [Reference Citation Analysis]
279 Jardim DL, Gagliato Dde M, Ribeiro KB, Shimada AK, Katz A. Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experience. Drugs R D 2012;12:207-16. [PMID: 23199211 DOI: 10.2165/11636760-000000000-00000] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
280 Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo. J Exp Clin Cancer Res. 2010;29:87. [PMID: 20594324 DOI: 10.1186/1756-9966-29-87] [Cited by in Crossref: 112] [Cited by in F6Publishing: 108] [Article Influence: 9.3] [Reference Citation Analysis]
281 Zhu X, Li H, Li S, Zhou M. Isolated Rare Urethral Metastasis From Primary Lung Adenocarcinoma: Case Report and Literature Review. Front Oncol 2019;9:784. [PMID: 31482069 DOI: 10.3389/fonc.2019.00784] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
282 Zhang J, Liu J, Chen H, Wu W, Li X, Wu Y, Zhang K, Gu L. The impact of histological types on the efficacy of angiogenesis inhibitors in the treatment of advanced NSCLC: a meta-analysis of randomized controlled trials. Onco Targets Ther 2015;8:2375-82. [PMID: 26366091 DOI: 10.2147/OTT.S90407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
283 Belani CP, Yamamoto N, Bondarenko IM, Poltoratskiy A, Novello S, Tang J, Bycott P, Niethammer AG, Ingrosso A, Kim S, Scagliotti GV. Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer 2014;14:290. [PMID: 24766732 DOI: 10.1186/1471-2407-14-290] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
284 Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012;109:17561-6. [PMID: 23045683 DOI: 10.1073/pnas.1215397109] [Cited by in Crossref: 487] [Cited by in F6Publishing: 470] [Article Influence: 48.7] [Reference Citation Analysis]
285 Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009;75:156-63. [PMID: 19167838 DOI: 10.1016/j.ijrobp.2008.10.043] [Cited by in Crossref: 261] [Cited by in F6Publishing: 236] [Article Influence: 20.1] [Reference Citation Analysis]
286 Burris H, Stephenson J, Otterson GA, Stein M, McGreivy J, Sun YN, Ingram M, Ye Y, Schwartzberg LS. Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer. J Oncol 2011;2011:853931. [PMID: 21559248 DOI: 10.1155/2011/853931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
287 Goto K, Endo M, Kusumoto M, Yamamoto N, Ohe Y, Shimizu A, Fukuoka M. Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis. Cancer Sci 2016;107:1837-42. [PMID: 27714941 DOI: 10.1111/cas.13096] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
288 Schultheis A, Wolf J, Büttner R. [Lung cancer. Molecular pathology and personalized therapy]. Internist (Berl) 2013;54:179-80, 182-7. [PMID: 23371257 DOI: 10.1007/s00108-012-3151-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
289 Pimple S, Manjappa AS, Ukawala M, Murthy RS. PLGA nanoparticles loaded with etoposide and quercetin dihydrate individually: in vitro cell line study to ensure advantage of combination therapy. Cancer Nanotechnol 2012;3:25-36. [PMID: 26069494 DOI: 10.1007/s12645-012-0027-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
290 Zhang J, Wu D, Zhang Z, Long J, Tian G, Wang Y, Ma X, Chen X, Han J, Hu W, Dai L, Nie J, Fang J. Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study. Technol Cancer Res Treat 2021;20:15330338211039676. [PMID: 34821175 DOI: 10.1177/15330338211039676] [Reference Citation Analysis]
291 Mediavilla-Varela M, Castro J, Chiappori A, Noyes D, Hernandez DC, Allard B, Stagg J, Antonia SJ. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. Neoplasia 2017;19:530-6. [PMID: 28582704 DOI: 10.1016/j.neo.2017.02.004] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
292 Tan AR, Dowlati A, Stein MN, Jones SF, Infante JR, Bendell J, Kane MP, Levinson KT, Suttle AB, Burris HA 3rd. Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. Br J Cancer 2014;110:2647-54. [PMID: 24800949 DOI: 10.1038/bjc.2014.233] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
293 Cardarella S, Johnson BE. The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med 2013;188:770-5. [PMID: 23841470 DOI: 10.1164/rccm.201305-0843PP] [Cited by in Crossref: 74] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
294 Keating NL, Huskamp HA, Schrag D, McWilliams JM, McNeil BJ, Landon BE, Chernew ME, Normand ST. Diffusion of Bevacizumab Across Oncology Practices: An Observational Study. Med Care 2018;56:69-77. [PMID: 29135615 DOI: 10.1097/MLR.0000000000000840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
295 Hernández-Agudo E, Mondejar T, Soto-Montenegro ML, Megías D, Mouron S, Sanchez J, Hidalgo M, Lopez-Casas PP, Mulero F, Desco M, Quintela-Fandino M. Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET. Mol Oncol 2016;10:704-18. [PMID: 26778791 DOI: 10.1016/j.molonc.2015.12.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
296 Al Farsi A, Ellis PM. Anti-angiogenic therapy in advanced non-small cell lung carcinoma (NSCLC): is there a role in subsequent lines of therapy? J Thorac Dis 2015;7:214-6. [PMID: 25922692 DOI: 10.3978/j.issn.2072-1439.2015.01.41] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
297 Eveno C, Soyer P, Teixeira L, Staudacher L, Pocard M. Anastomotic dehiscence during treatment with bevacizumab 5 years after colo-anal anastomosis with proposition for management without stopping chemotherapy. Clin Res Hepatol Gastroenterol 2011;35:594-6. [PMID: 21816701 DOI: 10.1016/j.clinre.2011.04.011] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
298 Mitchell AP, Kinlaw AC, Peacock-Hinton S, Dusetzina SB, Sanoff HK, Lund JL. Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. Oncologist 2020;25:46-54. [PMID: 31611329 DOI: 10.1634/theoncologist.2019-0338] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
299 Gold KA, Kim ES, Lee JJ, Wistuba II, Farhangfar CJ, Hong WK. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila) 2011;4:962-72. [PMID: 21733820 DOI: 10.1158/1940-6207.CAPR-11-0232] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
300 Velez M, Arango BA, Perez CA, Santos ES. Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer. Clin Med Insights Oncol 2012;6:117-24. [PMID: 22412303 DOI: 10.4137/CMO.S6248] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
301 Li H, Ha HL, Ding X, Bae C, Gazy N, Hao J, Zhong L. DMH4, a VEGFR2 inhibitor, effectively suppresses growth and invasion of lung cancer cells. J Appl Biomed 2018;16:46-50. [DOI: 10.1016/j.jab.2017.10.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
302 Kanthala S, Pallerla S, Jois S. Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors. Future Oncol 2015;11:865-78. [PMID: 25757687 DOI: 10.2217/fon.14.312] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
303 Kaburaki K, Isobe K, Kobayashi H, Yoshizawa T, Takai Y, Homma S. A feasibility study of bevacizumab and vinorelbine in patients with previously treated advanced non-squamous non-small-cell lung cancer. Mol Clin Oncol 2017;6:510-4. [PMID: 28413657 DOI: 10.3892/mco.2017.1187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
304 Zhang S, Xiang X, Liu L, Yang H, Cen D, Tang G. Bioinformatics Analysis of Hub Genes and Potential Therapeutic Agents Associated with Gastric Cancer. Cancer Manag Res 2021;13:8929-51. [PMID: 34876855 DOI: 10.2147/CMAR.S341485] [Reference Citation Analysis]
305 Isaka T, Nakayama H, Yokose T, Ito H, Katayama K, Yamada K, Masuda M. Platinum-Based Adjuvant Chemotherapy for Stage II and Stage III Squamous Cell Carcinoma of the Lung. Ann Thorac Cardiovasc Surg 2017;23:19-25. [PMID: 28025447 DOI: 10.5761/atcs.oa.16-00164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
306 Sánchez Hernández A, José Juan O, Vidal Martínez J, Blanco R, Maciá S, Esquerdo Galiana G, Aparisi Aparisi F, Garde Noguera J, Catot S, Losa Gaspá F, García-Piñon F. Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma. Clin Transl Oncol 2015;17:281-8. [PMID: 25236392 DOI: 10.1007/s12094-014-1223-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
307 Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer J, Atkins J, Pallares C, Burgess R, Tye L, Selaru P, Wang E, Chao R, Govindan R. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009;101:1543-8. [PMID: 19826424 DOI: 10.1038/sj.bjc.6605346] [Cited by in Crossref: 104] [Cited by in F6Publishing: 102] [Article Influence: 8.0] [Reference Citation Analysis]
308 Provencio M, Carcereny E, Artal Á. Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. Clin Transl Oncol 2019;21:1464-71. [PMID: 30903517 DOI: 10.1007/s12094-019-02072-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
309 Kang F, Wang Z, Li G, Wang S, Liu D, Zhang M, Zhao M, Yang W, Wang J. Inter-heterogeneity and intra-heterogeneity of αvβ3 in non-small cell lung cancer and small cell lung cancer patients as revealed by 68Ga-RGD2 PET imaging. Eur J Nucl Med Mol Imaging 2017;44:1520-8. [PMID: 28405726 DOI: 10.1007/s00259-017-3696-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
310 Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA Jr, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008;26:3351-7. [PMID: 18612151 DOI: 10.1200/JCO.2007.14.0111] [Cited by in Crossref: 225] [Cited by in F6Publishing: 81] [Article Influence: 16.1] [Reference Citation Analysis]
311 Graham DM, Leighl NB. Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. Front Oncol 2014;4:258. [PMID: 25295228 DOI: 10.3389/fonc.2014.00258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
312 Dansin E, Lauridant G, Chahine B. [Antiangiogenic agents: current limits in thoracic oncology]. Bull Cancer 2012;99:1083-91. [PMID: 23113985 DOI: 10.1684/bdc.2012.1655] [Reference Citation Analysis]
313 Chan HT, Chin YM, Low SK. The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics. Oncol Ther 2019;7:1-32. [PMID: 32700193 DOI: 10.1007/s40487-018-0090-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
314 Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622. [PMID: 20606091 DOI: 10.1200/jco.2010.28.1386] [Cited by in Crossref: 562] [Cited by in F6Publishing: 331] [Article Influence: 46.8] [Reference Citation Analysis]
315 Jinru XM, Yu YM, Bo JM, Linxue QM, Xian-quan SP. Identification of Key Genes Between Lung Adenocarcinoma and Lung Squamous Cell Carcinoma by Bioinformatics Analysis. Advanced Ultrasound in Diagnosis and Therapy 2020;4:335. [DOI: 10.37015/audt.2020.200011] [Reference Citation Analysis]
316 Oda Y, Narukawa M. Response rate of anticancer drugs approved by the Food and Drug Administration based on a single-arm trial. BMC Cancer 2022;22:277. [PMID: 35291959 DOI: 10.1186/s12885-022-09383-w] [Reference Citation Analysis]
317 Green MR, Dowlati A, Yellamraju L, Daniels L, Willey J, Andrews M, Leff R. Irinotecan-cisplatin therapy for patients with extensive-stage small cell lung cancer: use patterns among American medical oncologists 2000-2006. J Thorac Oncol 2007;2:953-6. [PMID: 17909359 DOI: 10.1097/JTO.0b013e318153f8db] [Reference Citation Analysis]
318 Takahashi S, Okuma Y, Watanabe K, Hosomi Y, Imamura A, Okamura T, Gemma A. Single-institutional experience of clinicopathological analysis and treatment for lung cancer patients with human immunodeficiency virus infection. Mol Clin Oncol 2017;6:765-9. [PMID: 28515928 DOI: 10.3892/mco.2017.1214] [Reference Citation Analysis]
319 Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312-1327. [PMID: 18821591 DOI: 10.1002/hep.22506] [Cited by in Crossref: 747] [Cited by in F6Publishing: 709] [Article Influence: 53.4] [Reference Citation Analysis]
320 Prager GW, Poettler M, Unseld M, Zielinski CC. Angiogenesis in cancer: Anti-VEGF escape mechanisms. Transl Lung Cancer Res. 2012;1:14-25. [PMID: 25806151 DOI: 10.3978/j.issn.2218-6751.2011.11.02] [Cited by in F6Publishing: 33] [Reference Citation Analysis]
321 An J, Tang CH, Wang N, Liu Y, Lv J, Xu B, Li XY, Guo WF, Gao HJ, He K, Liu XQ. Serum peptide expression and treatment responses in patients with advanced non-small-cell lung cancer. Oncol Lett 2018;15:9307-16. [PMID: 29844828 DOI: 10.3892/ol.2018.8460] [Reference Citation Analysis]
322 Levitt MR, Levitt R, Silbergeld DL. Controversies in the management of brain metastases. Surg Neurol Int 2013;4:S231-5. [PMID: 23717794 DOI: 10.4103/2152-7806.111300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
323 Yang WH, Xu J, Mu JB, Xie J. Revision of the concept of anti-angiogenesis and its applications in tumor treatment. Chronic Dis Transl Med 2017;3:33-40. [PMID: 29063054 DOI: 10.1016/j.cdtm.2017.01.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
324 Asami K, Okishio K, Kawaguchi T, Atagi S. Personalized maintenance therapy in advanced non-small cell lung cancer. Transl Lung Cancer Res 2013;2:452-6. [PMID: 25806269 DOI: 10.3978/j.issn.2218-6751.2013.10.16] [Reference Citation Analysis]
325 Zahn MO, Linck D, Losem C, Gessner C, Metze H, Gaillard VE, Tessen HW. AVAiLABLE NIS - AVASTIN® in lung cancer treatment in routine oncology practice in Germany. BMC Cancer 2019;19:433. [PMID: 31077164 DOI: 10.1186/s12885-019-5618-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
326 Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, Tong Z, Wang S, Li J, Wang Z. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 2014;14:820. [PMID: 25376790 DOI: 10.1186/1471-2407-14-820] [Cited by in Crossref: 99] [Cited by in F6Publishing: 123] [Article Influence: 12.4] [Reference Citation Analysis]
327 Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, Rodabough RJ, Chien JW, Wactawski-Wende J, Gass M, Kotchen JM, Johnson KC, O'Sullivan MJ, Ockene JK, Chen C, Hubbell FA; Women's Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009;374:1243-51. [PMID: 19767090 DOI: 10.1016/S0140-6736(09)61526-9] [Cited by in Crossref: 188] [Cited by in F6Publishing: 95] [Article Influence: 14.5] [Reference Citation Analysis]
328 Mansfield AS, Nevala WK, Lieser EA, Leontovich AA, Markovic SN. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology 2013;2:e24436. [PMID: 23762809 DOI: 10.4161/onci.24436] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
329 Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-8. [PMID: 17982442 DOI: 10.1038/nature06358] [Cited by in Crossref: 780] [Cited by in F6Publishing: 733] [Article Influence: 52.0] [Reference Citation Analysis]
330 Dy GK, Molina JR, Qi Y, Ansari R, Thomas S, Ross HJ, Soori G, Anderson D, Aubry MC, Meyers J, Adjei AA, Mandrekar S, Adjei AA. NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. J Thorac Oncol 2014;9:1146-53. [PMID: 25157767 DOI: 10.1097/JTO.0000000000000217] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
331 Li SD, Martial A, Schrock AB, Liu JJ. Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma. Exp Hematol Oncol 2017;6:29. [PMID: 29142786 DOI: 10.1186/s40164-017-0089-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
332 Piperdi B, Walsh WV, Bradley K, Zhou Z, Bathini V, Hanrahan-Boshes M, Hutchinson L, Perez-Soler R. Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol 2012;7:1032-40. [PMID: 22534815 DOI: 10.1097/JTO.0b013e31824de2fa] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
333 Majeti BK, Lee JH, Simmons BH, Shojaei F. VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma. BMC Cancer 2013;13:213. [PMID: 23627488 DOI: 10.1186/1471-2407-13-213] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
334 Jha PK, Vankalakunti M, Siddini V, Bonu R, Prakash GK, Babu K, Ballal HS. Sunitinib induced nephrotic syndrome and thrombotic microangiopathy. Indian J Nephrol 2013;23:67-70. [PMID: 23580811 DOI: 10.4103/0971-4065.107215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
335 Metro G, Crinò L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res 2012;1:5-13. [PMID: 25806150 DOI: 10.3978/j.issn.2218-6751.2011.12.01] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
336 Cui J, Cai X, Zhu M, Liu T, Zhao N. The efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30 randomized controlled clinical trials. PLoS One 2013;8:e62038. [PMID: 23614008 DOI: 10.1371/journal.pone.0062038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
337 Pruis MA, von der Thüsen JH, Dubbink HJ. MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer? Ann Transl Med 2020;8:1538. [PMID: 33313283 DOI: 10.21037/atm-20-3763] [Reference Citation Analysis]
338 He J, Pan H, He J, Li S. Effectiveness and safety of bevacizumab in extensive-disease small cell lung cancer: a systemic review and meta-analysis. Ann Transl Med 2021;9:1285. [PMID: 34532422 DOI: 10.21037/atm-21-963] [Reference Citation Analysis]
339 Takagi Y, Hosomi Y, Oshita F, Okamoto H, Seki N, Minato K, Aono H, Yamada K, Okuma Y, Hida N, Sakamoto T, Miura Y, Yomota M, Satoh A, Kunitoh H, Sakamaki K, Shibuya M, Watanabe K. Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014. BMC Cancer 2015;15:740. [PMID: 26481215 DOI: 10.1186/s12885-015-1756-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
340 Medinger M, Mross K. Clinical trials with anti-angiogenic agents in hematological malignancies. J Angiogenes Res 2010;2:10. [PMID: 20569499 DOI: 10.1186/2040-2384-2-10] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
341 Daaboul N, Nicholas G, Laurie SA. Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview. Curr Oncol 2018;25:S77-85. [PMID: 29910650 DOI: 10.3747/co.25.3792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
342 Taira K, Nadatani Y, Hirano S, Maeda K, Fujiwara Y. Large Skin Ulcer and Delayed Wound Healing around a Colostomy in a Patient with Metastatic Colorectal Cancer Receiving Vascular Endothelial Growth Factor Receptor-2 Inhibitor Therapy. Case Rep Oncol 2019;12:370-5. [PMID: 31182953 DOI: 10.1159/000500412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
343 Hsiao SH, Chen WT, Chung CL, Chou YT, Lin SE, Hong SY, Chang JH, Chang TH, Chien LN. Comparative survival analysis of platinum-based adjuvant chemotherapy for early-stage squamous cell carcinoma and adenocarcinoma of the lung. Cancer Med 2022. [PMID: 35274494 DOI: 10.1002/cam4.4570] [Reference Citation Analysis]
344 Arimoto A, Uehara K, Tsuzuki T, Aiba T, Ebata T, Nagino M. Role of bevacizumab in neoadjuvant chemotherapy and its influence on microvessel density in rectal cancer. Int J Clin Oncol 2015;20:935-42. [PMID: 25788218 DOI: 10.1007/s10147-015-0818-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
345 Jin Y, Wei L, Jiang Q, Song X, Teng C, Fan C, Lv Y, Liu Y, Shen W, Li L, Huang D, Xin T. Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model. Sci Rep 2018;8:15837. [PMID: 30367145 DOI: 10.1038/s41598-018-34030-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
346 Kruzliak P, Kovacova G, Pechanova O. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension. Angiogenesis 2013;16:289-95. [PMID: 23203441 DOI: 10.1007/s10456-012-9327-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
347 Stroyakovskiy DL, Fadeeva NV, Matrosova MP, Shelepen KG, Adamchuk GA, Roy B, Nagarkar R, Kalloli M, Zhuravleva D, Voevodin GD, Shustova MS, Kryukov F. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab. BMC Cancer 2022;22:129. [PMID: 35105329 DOI: 10.1186/s12885-022-09243-7] [Reference Citation Analysis]
348 Huang C, Wang X, Wang J, Lin L, Liu Z, Xu W, Wang L, Xiao J, Li K. Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor. Thorac Cancer 2014;5:438-46. [PMID: 26767036 DOI: 10.1111/1759-7714.12115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
349 Nihei S, Asaka J, Takahashi H, Kudo K. Bevacizumab Increases Endothelin-1 Production via Forkhead Box Protein O1 in Human Glomerular Microvascular Endothelial Cells In Vitro. Int J Nephrol 2021;2021:8381115. [PMID: 34912580 DOI: 10.1155/2021/8381115] [Reference Citation Analysis]
350 Volk LD, Flister MJ, Bivens CM, Stutzman A, Desai N, Trieu V, Ran S. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia 2008;10:613-23. [PMID: 18516298 DOI: 10.1593/neo.08302] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 4.0] [Reference Citation Analysis]
351 Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong MT, Saxman S, Kelaghan J, Bleyer A, Fisch MJ. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst 2010;102:859-65. [PMID: 20505152 DOI: 10.1093/jnci/djq179] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 4.1] [Reference Citation Analysis]
352 Phairatana T, Leong CL, Gowers SA, Patel BA, Boutelle MG. Real-time detection of carboplatin using a microfluidic system. Analyst 2016;141:6270-7. [PMID: 27796386 DOI: 10.1039/c6an01446a] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
353 Zhu C, Xing XX, Wu B, Liang G, Han G, Lin CX, Fang HM. Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB-IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China. Front Pharmacol 2021;12:735536. [PMID: 35002693 DOI: 10.3389/fphar.2021.735536] [Reference Citation Analysis]
354 Yoo SA, Kwok SK, Kim WU. Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm 2008;2008:129873. [PMID: 19223981 DOI: 10.1155/2008/129873] [Cited by in Crossref: 48] [Cited by in F6Publishing: 62] [Article Influence: 3.7] [Reference Citation Analysis]
355 Varol U, Oktay E, Yildirim M, Surmeli ZG, Dirican A, Meydan N, Karaca B, Karabulut B, Uslu R. Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer. Mol Clin Oncol 2014;2:166-70. [PMID: 24649328 DOI: 10.3892/mco.2013.212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
356 Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. PLoS One 2010;5:e12417. [PMID: 20856855 DOI: 10.1371/journal.pone.0012417] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
357 Awasthi N, Schwarz RE. Profile of nintedanib in the treatment of solid tumors: the evidence to date. Onco Targets Ther. 2015;8:3691-3701. [PMID: 26677336 DOI: 10.2147/OTT.S78805] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
358 Dy GK, Hillman SL, Rowland KM Jr, Molina JR, Steen PD, Wender DB, Nair S, Mandrekar S, Schild SE, Adjei AA; North Central Cancer Treatment Group Study N0326. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer 2010;116:5686-93. [PMID: 21218460 DOI: 10.1002/cncr.25448] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
359 Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell 2017;31:487-500.e8. [PMID: 28366679 DOI: 10.1016/j.ccell.2017.02.018] [Cited by in Crossref: 150] [Cited by in F6Publishing: 147] [Article Influence: 30.0] [Reference Citation Analysis]
360 Webb JD, Simon MC. Novel insights into the molecular origins and treatment of lung cancer. Cell Cycle 2010;9:4098-105. [PMID: 20962595 DOI: 10.4161/cc.9.20.13588] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
361 Kruijff S, Bastiaannet E, Brouwers AH, Nagengast WB, Speijers MJ, Suurmeijer AJ, Hospers GA, Hoekstra HJ. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma. Ann Surg Oncol 2012;19:620-6. [PMID: 21861214 DOI: 10.1245/s10434-011-2027-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
362 Ding W, Chen X, Yang L, Chen Y, Song J, Bu W, Feng B, Zhang M, Luo Y, Jia X, Feng L. Combination of ShuangDan Capsule and Sorafenib Inhibits Tumor Growth and Angiogenesis in Hepatocellular Carcinoma Via PI3K/Akt/mTORC1 Pathway. Integr Cancer Ther 2022;21:15347354221078888. [PMID: 35234063 DOI: 10.1177/15347354221078888] [Reference Citation Analysis]
363 Yang L, Liu L, Zhu YH, Wang BB, Chen YN, Zhang F, Zhang XA, Ren CC. Neuropilin-1 is associated with the prognosis of cervical cancer in Henan Chinese population. Onco Targets Ther 2019;12:2911-20. [PMID: 31114235 DOI: 10.2147/OTT.S194349] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
364 Hamada S, Ichiyasu H, Ikeda T, Inaba M, Kashiwabara K, Sadamatsu T, Sato N, Akaike K, Okabayashi H, Saruwatari K, Tomita Y, Saeki S, Hirata N, Yoshinaga T, Fujii K. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer. BMC Pulm Med 2019;19:72. [PMID: 30940113 DOI: 10.1186/s12890-019-0838-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
365 Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, Stewart DJ, Hicks ME, Erasmus J Jr, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53. [PMID: 22586319 DOI: 10.1158/2159-8274.CD-10-0010] [Cited by in Crossref: 595] [Cited by in F6Publishing: 297] [Article Influence: 54.1] [Reference Citation Analysis]
366 Tomimoto H, Hanibuchi M, Ogushi F, Okano Y, Shinohara T, Doi H, Yamamoto A, Takeuchi E, Yamamoto A, Azuma M, Tada H, Kanematsu T, Kakiuchi S, Goto H, Yano S, Nishioka Y, Sone S. A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. Oncol Lett 2011;2:465-70. [PMID: 22866104 DOI: 10.3892/ol.2011.266] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
367 Fraioli F, Anzidei M, Serra G, Liberali S, Fiorelli A, Zaccagna F, Longo F, Anile M, Catalano C. Whole-tumour CT-perfusion of unresectable lung cancer for the monitoring of anti-angiogenetic chemotherapy effects. Br J Radiol 2013;86:20120174. [PMID: 23908346 DOI: 10.1259/bjr.20120174] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
368 Tiseo M, Bartolotti M, Gelsomino F, Bordi P. Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC). Drug Des Devel Ther 2010;4:81-98. [PMID: 20531963 DOI: 10.2147/dddt.s6594] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
369 Pirker R. Chemotherapy: advanced NSCLC--should we use doublets in elderly patients? Nat Rev Clin Oncol 2011;8:694-6. [PMID: 21946845 DOI: 10.1038/nrclinonc.2011.147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
370 Gupta N, Hatoum H, Dy GK. First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel. Int J Nanomedicine 2014;9:209-21. [PMID: 24399877 DOI: 10.2147/IJN.S41770] [Cited by in Crossref: 15] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
371 Boni C, Tiseo M, Boni L, Baldini E, Recchia F, Barone C, Grossi F, Germano D, Matano E, Marini G, Labianca R, Di Costanzo F, Bagnulo A, Pennucci C, Caroti C, Mencoboni M, Zanelli F, Prochilo T, Cafferata MA, Ardizzoni A; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). Br J Cancer 2012;106:658-65. [PMID: 22240782 DOI: 10.1038/bjc.2011.606] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
372 Laurie SA, Goss GD. Reply to F. Gelsomino et al. J Clin Oncol 2013;31:3293-4. [PMID: 23943831 DOI: 10.1200/JCO.2013.50.8705] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
373 Michaelson MD, Zhu AX, Ryan DP, McDermott DF, Shapiro GI, Tye L, Chen I, Stephenson P, Patyna S, Ruiz-Garcia A, Schwarzberg AB. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. Br J Cancer 2013;108:1393-401. [PMID: 23511559 DOI: 10.1038/bjc.2013.96] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
374 Cao Y. VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs. Nat Rev Endocrinol. 2014;10:530-539. [PMID: 25048037 DOI: 10.1038/nrendo.2014.114] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
375 Shiozawa T, Iyama S, Toshima S, Sakata A, Usui S, Minami Y, Sato Y, Hizawa N, Noguchi M. Dimethylarginine dimethylaminohydrolase 2 promotes tumor angiogenesis in lung adenocarcinoma. Virchows Arch 2016;468:179-90. [PMID: 26515557 DOI: 10.1007/s00428-015-1863-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
376 Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2014;20:4210-4217. [PMID: 25125258 DOI: 10.1158/1078-0432.ccr-14-0521] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
377 Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol 2012;107:155-64. [PMID: 21986722 DOI: 10.1007/s11060-011-0722-2] [Cited by in Crossref: 101] [Cited by in F6Publishing: 95] [Article Influence: 9.2] [Reference Citation Analysis]
378 Kyle F, Spicer J. Targeted therapies in non-small cell lung cancer. Cancer Imaging 2008;8:199-205. [PMID: 19028612 DOI: 10.1102/1470-7330.2008.0027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
379 Hillman GG, Lonardo F, Hoogstra DJ, Rakowski J, Yunker CK, Joiner MC, Dyson G, Gadgeel S, Singh-Gupta V. Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors. Transl Oncol 2014:S1936-5233(14)00037-0. [PMID: 24862536 DOI: 10.1016/j.tranon.2014.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
380 Qiu ZX, Wang L, Han J, Liu D, Huang W, Altaf K, Qiu XS, Javed MA, Zheng J, Chen BJ, Li WM. Prognostic impact of Raf-1 and p-Raf-1 expressions for poor survival rate in non-small cell lung cancer. Cancer Sci 2012;103:1774-9. [PMID: 22738312 DOI: 10.1111/j.1349-7006.2012.02375.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
381 Duda DG. Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer. ISRN Cell Biol 2012;2012:587259. [PMID: 24340224 DOI: 10.5402/2012/587259] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
382 Nozawa K, Takatsuka D, Endo Y, Horisawa N, Ozaki Y, Kataoka A, Kotani H, Yoshimura A, Hattori M, Sawaki M, Iwata H. Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 2022;:103703. [PMID: 35533814 DOI: 10.1016/j.critrevonc.2022.103703] [Reference Citation Analysis]
383 Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18. [DOI: 10.1038/nrclinonc.2009.110] [Cited by in Crossref: 257] [Cited by in F6Publishing: 224] [Article Influence: 19.8] [Reference Citation Analysis]
384 Kuo YH, Lin CH, Shau WY, Chen TJ, Yang SH, Huang SM, Hsu C, Lu YS, Cheng AL. Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy. BMC Cancer 2012;12:620. [PMID: 23268621 DOI: 10.1186/1471-2407-12-620] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
385 Hakozaki T, Okuma Y, Hashimoto K, Hosomi Y. Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis. J Cancer Res Clin Oncol 2019;145:2555-64. [PMID: 31350622 DOI: 10.1007/s00432-019-02985-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
386 Langhammer S, Scheerer J. Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. Oncotarget 2017;8:43555-70. [PMID: 28402937 DOI: 10.18632/oncotarget.16674] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
387 Yang Y, Luo Z, Qin Y, Zhou Y, Gong L, Huang J, Wang H. Production of bFGF monoclonal antibody and its inhibition of metastasis in Lewis lung carcinoma. Mol Med Rep 2017;16:4015-21. [PMID: 28765892 DOI: 10.3892/mmr.2017.7099] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
388 Remon J, Lacas B, Herbst R, Reck M, Garon EB, Scagliotti GV, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen HJ, Heymach JV, Mandrekar SJ, Okamoto I, Neal JW, Heist RS, Planchard D, Pignon J, Besse B, Besse B, Lacas B, Pignon J, Remon J, Berghmans T, Dahlberg S, Felip E, Berghmans T, Besse B, Dahlberg S, Felip E, Garon E, Groen HJ, Hanna N, Heist RS, Herbst R, Heymach JV, Lacas B, Adjei AA, Heist R, Mandrekar SJ, Neal JW, Okamoto I, Pignon J, Ramlau R, Remon J, Reck M, Scagliotti GV, Vansteenkiste J, Yoh K. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. European Journal of Cancer 2022;166:112-25. [DOI: 10.1016/j.ejca.2022.02.002] [Reference Citation Analysis]
389 Kovács K, Decatur C, Toro M, Pham DG, Liu H, Jing Y, Murray TG, Lampidis TJ, Merchan JR. 2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3β Activation. Mol Cancer Ther 2016;15:264-75. [PMID: 26637370 DOI: 10.1158/1535-7163.MCT-14-0315] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
390 Starlinger P, Brugger P, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann SF, Gnant M, Brostjan C. Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment. Neoplasia 2011;13:419-27. [PMID: 21532882 DOI: 10.1593/neo.101508] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
391 Barrett CL, Schwab RB, Jung H, Crain B, Goff DJ, Jamieson CH, Thistlethwaite PA, Harismendy O, Carson DA, Frazer KA. Transcriptome sequencing of tumor subpopulations reveals a spectrum of therapeutic options for squamous cell lung cancer. PLoS One 2013;8:e58714. [PMID: 23527012 DOI: 10.1371/journal.pone.0058714] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
392 Yimaer W, Abudouyimu A, Tian Y, Magaoweiya S, Bagedati D, Wen H. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther 2016;9:1167-73. [PMID: 27022276 DOI: 10.2147/OTT.S102265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
393 Deng S, Zhang G, Kuai J, Fan P, Wang X, Zhou P, Yang D, Zheng X, Liu X, Wu Q, Huang Y. Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner. J Exp Clin Cancer Res 2018;37:260. [PMID: 30373628 DOI: 10.1186/s13046-018-0932-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
394 Guyot M, Hilmi C, Ambrosetti D, Merlano M, Lo Nigro C, Durivault J, Grépin R, Pagès G. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies. Oncotarget 2017;8:9174-88. [PMID: 27999187 DOI: 10.18632/oncotarget.13942] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
395 Villaruz LC, Socinski MA. The role of anti-angiogenesis in non-small-cell lung cancer: an update. Curr Oncol Rep 2015;17:26. [PMID: 25947099 DOI: 10.1007/s11912-015-0448-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
396 Liu C, Li P, Gao D, Zhou P, Shao Y, Zhang Q, Li W. Abnormal promoter methylation of multiple tumor suppressor genes in human bronchial epithelial malignant cells. Biomed Rep 2014;2:525-8. [PMID: 24944801 DOI: 10.3892/br.2014.268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
397 Liu YY, Chen T, Shen D, Zhang WY, Wang CG, Jiang JH, Zeng DX. Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review. J Int Med Res 2020;48:300060519887276. [PMID: 31847652 DOI: 10.1177/0300060519887276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
398 Honma HN, Perroud MW Jr, Leme MS, Barbeiro AS, Saad BA, Morcillo AM, Vassallo J, Costa DB, Zambon L. EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients. Target Oncol 2014;9:389-94. [PMID: 24793378 DOI: 10.1007/s11523-014-0314-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
399 Korn EL, Freidlin B, Mooney M. Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005. J Clin Oncol 2009;27:1712-21. [PMID: 19237631 DOI: 10.1200/JCO.2008.19.5339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
400 Carcereny E, Morán T, Capdevila L, Cros S, Vilà L, de Los Llanos Gil M, Remón J, Rosell R. The epidermal growth factor receptor (EGRF) in lung cancer. Transl Respir Med 2015;3:1. [PMID: 25810955 DOI: 10.1186/s40247-015-0013-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
401 Roviello G. The distinctive nature of adenocarcinoma of the lung. Onco Targets Ther 2015;8:2399-406. [PMID: 26366094 DOI: 10.2147/OTT.S89225] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
402 Jiang Z, Zhang Y, Yang Y, Yue Z, Pan Z. Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors. Thorac Cancer 2018;9:1151-5. [PMID: 30027579 DOI: 10.1111/1759-7714.12814] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
403 Pao W. New approaches to targeted therapy in lung cancer. Proc Am Thorac Soc 2012;9:72-3. [PMID: 22550248 DOI: 10.1513/pats.201112-054MS] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
404 Hu X, Wang L, Lin L, Han X, Dou G, Meng Z, Shi Y. A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. Chin J Cancer Res 2016;28:444-51. [PMID: 27647973 DOI: 10.21147/j.issn.1000-9604.2016.04.08] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
405 Lunacsek OE, Ravelo A, Coutinho AD, Hazard SJ, Green MR, Willey J, Eaddy M, Goertz HP. First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices. Drugs Real World Outcomes 2016;3:333-43. [PMID: 27747837 DOI: 10.1007/s40801-016-0090-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
406 Akita S, Hattori N, Masuda T, Horimasu Y, Nakashima T, Iwamoto H, Fujitaka K, Miyake M, Kohno N. MT95-4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse model. Cancer Sci 2015;106:921-8. [PMID: 25950387 DOI: 10.1111/cas.12692] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
407 Qiu Y, Jiang J, Zhang M, Qin Y. Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin. Oncol Lett 2019;18:161-8. [PMID: 31289485 DOI: 10.3892/ol.2019.10302] [Reference Citation Analysis]
408 Zugazagoitia J, Enguita AB, Nuñez JA, Iglesias L, Ponce S. The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects. J Thorac Dis 2014;6:S526-36. [PMID: 25349703 DOI: 10.3978/j.issn.2072-1439.2014.01.27] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
409 Grossi F. Management of non-small cell lung in cancer patients with stable disease. Drugs 2012;72 Suppl 1:20-7. [PMID: 22712794 DOI: 10.2165/1163013-S0-000000000-00000] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
410 Brodowicz T, O'Byrne K, Manegold C. Bone matters in lung cancer. Ann Oncol 2012;23:2215-22. [PMID: 22357445 DOI: 10.1093/annonc/mds009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
411 Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;101:1044-8. [PMID: 19564563 DOI: 10.1093/jnci/djp177] [Cited by in Crossref: 261] [Cited by in F6Publishing: 214] [Article Influence: 20.1] [Reference Citation Analysis]
412 Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, Coleman RL, Sood AK. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene 2018;37:722-31. [PMID: 29059175 DOI: 10.1038/onc.2017.348] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
413 Das M, Wakelee H. Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC. Transl Lung Cancer Res 2014;3:397-9. [PMID: 25806332 DOI: 10.3978/j.issn.2218-6751.2014.09.05] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
414 Tsoi M, Laguë MN, Boyer A, Paquet M, Nadeau MÈ, Boerboom D. Anti-VEGFA Therapy Reduces Tumor Growth and Extends Survival in a Murine Model of Ovarian Granulosa Cell Tumor. Transl Oncol 2013;6:226-33. [PMID: 23730402 DOI: 10.1593/tlo.13136] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
415 Gerber DE, Dahlberg SE, Sandler AB, Ahn DH, Schiller JH, Brahmer JR, Johnson DH. Baseline tumour measurements predict survival in advanced non-small cell lung cancer. Br J Cancer 2013;109:1476-81. [PMID: 23942074 DOI: 10.1038/bjc.2013.472] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
416 Desportes E, Wagner M, Kamal M, Salomon AV, Deniziaut G, Pierron G, Rouleau E, Jouffroy T, Le Tourneau C, Paoletti X, Servois V. Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial. Oncotarget 2017;8:1760-73. [PMID: 27655703 DOI: 10.18632/oncotarget.12051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
417 Agarwala AK, Hanna NH. Advanced non-small cell lung cancer: the role of maintenance therapy. Ther Adv Med Oncol 2010;2:17-23. [PMID: 21789123 DOI: 10.1177/1758834009351443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
418 Mori F, Ishida T, Ito A, Sato F, Masaki A, Takino H, Ri M, Kusumoto S, Komatsu H, Ueda R, Inagaki H, Iida S. Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model. Blood Cancer J 2012;2:e67. [PMID: 22829969 DOI: 10.1038/bcj.2012.12] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
419 Brown AP, Citrin DE, Camphausen KA. Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis Rev 2008;27:415-34. [PMID: 18414993 DOI: 10.1007/s10555-008-9143-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
420 Wozney JL, Antonarakis ES. Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev 2014;33:581-94. [PMID: 24402967 DOI: 10.1007/s10555-013-9475-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
421 Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin. 2010;60:222-243. [PMID: 20554717 DOI: 10.3322/caac.20075] [Cited by in Crossref: 311] [Cited by in F6Publishing: 273] [Article Influence: 25.9] [Reference Citation Analysis]
422 Kawata E, Ashihara E, Maekawa T. RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers. J Clin Bioinforma 2011;1:6. [PMID: 21884621 DOI: 10.1186/2043-9113-1-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
423 Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli C, Caraglia M, Tassone P, Tagliaferri P, Correale P. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther 2013;14:469-75. [PMID: 23760488 DOI: 10.4161/cbt.24425] [Cited by in Crossref: 54] [Cited by in F6Publishing: 61] [Article Influence: 6.8] [Reference Citation Analysis]
424 Espana-Serrano L, Chougule MB. Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non-small-cell Lung Cancer. Mol Ther Nucleic Acids 2016;5:e384. [PMID: 27845769 DOI: 10.1038/mtna.2016.90] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
425 Hirai F, Edagawa M, Shimamatsu S, Toyozawa R, Toyokawa G, Nosaki K, Yamaguchi M, Seto T, Takenoyama M, Ichinose Y. Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type. Oncol Lett 2017;14:306-12. [PMID: 28693169 DOI: 10.3892/ol.2017.6118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
426 Langley RR, Fidler IJ. The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 2011;128:2527-2535. [PMID: 21365651 DOI: 10.1002/ijc.26031] [Cited by in Crossref: 481] [Cited by in F6Publishing: 458] [Article Influence: 43.7] [Reference Citation Analysis]
427 Chen J, Chen J, Wu X, Shi T, Kang M. Efficacy of targeted agents in the treatment of elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis. Onco Targets Ther 2016;9:4797-803. [PMID: 27536143 DOI: 10.2147/OTT.S100618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
428 Senellart H, Bennouna J. [Thrombo-embolic risks and bevacizumab: data from the literature and recommendations for the use of anticoagulants and antiaggregants]. Rev Mal Respir 2008;25:1027-30. [PMID: 18971808 DOI: 10.1016/s0761-8425(08)74418-8] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
429 Zhang SD, McCrudden CM, Kwok HF. Prognostic significance of combining VEGFA, FLT1 and KDR mRNA expression in lung cancer. Oncol Lett 2015;10:1893-901. [PMID: 26622771 DOI: 10.3892/ol.2015.3415] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
430 Togashi Y, Hayashi H, Nakagawa K, Nishio K. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence. Drug Des Devel Ther. 2014;8:1037-1046. [PMID: 25114510 DOI: 10.2147/dddt.s50358] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
431 Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010;15:539-547. [PMID: 20511320 DOI: 10.1634/theoncologist.2009-0274] [Cited by in Crossref: 89] [Cited by in F6Publishing: 79] [Article Influence: 7.4] [Reference Citation Analysis]
432 Bloch O, Safaee M, Sun MZ, Butowski NA, McDermott MW, Berger MS, Aghi MK, Parsa AT. Disseminated progression of glioblastoma after treatment with bevacizumab. Clin Neurol Neurosurg 2013;115:1795-801. [PMID: 23706614 DOI: 10.1016/j.clineuro.2013.04.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
433 Bodor JN, Boumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer 2020;126:260-70. [PMID: 31691957 DOI: 10.1002/cncr.32468] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 15.3] [Reference Citation Analysis]
434 Reimann M, Folprecht G, Haase R, Trautmann K, Ehninger G, Reichmann H, Ziemssen F, Ziemssen T. Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study. Exp Transl Stroke Med 2013;5:7. [PMID: 23668549 DOI: 10.1186/2040-7378-5-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
435 Nelson V, Ziehr J, Agulnik M, Johnson M. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther 2013;6:135-43. [PMID: 23493883 DOI: 10.2147/OTT.S23165] [Cited by in Crossref: 7] [Cited by in F6Publishing: 26] [Article Influence: 0.8] [Reference Citation Analysis]
436 Mitamura T, Gourley C, Sood AK. Prediction of anti-angiogenesis escape. Gynecol Oncol 2016;141:80-5. [PMID: 26748214 DOI: 10.1016/j.ygyno.2015.12.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
437 Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res 2011;17:372-81. [PMID: 21224365 DOI: 10.1158/1078-0432.CCR-10-1791] [Cited by in Crossref: 77] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
438 Neal JW. Histology matters: individualizing treatment in non-small cell lung cancer. Oncologist 2010;15:3-5. [PMID: 20086166 DOI: 10.1634/theoncologist.2009-0306] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
439 Ramalingam SS, Dahlberg SE, Belani CP, Saltzman JN, Pennell NA, Nambudiri GS, McCann JC, Winegarden JD, Kassem MA, Mohamed MK, Rothman JM, Lyss AP, Horn L, Stinchcombe TE, Schiller JH. Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. J Clin Oncol 2019;37:2360-7. [PMID: 31361535 DOI: 10.1200/JCO.19.01006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
440 Resch T, Pircher A, Kähler CM, Pratschke J, Hilbe W. Endothelial progenitor cells: current issues on characterization and challenging clinical applications. Stem Cell Rev Rep 2012;8:926-39. [PMID: 22095429 DOI: 10.1007/s12015-011-9332-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
441 Schad F, Thronicke A, Steele ML, Merkle A, Matthes B, Grah C, Matthes H. Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS One. 2018;13:e0203058. [PMID: 30148853 DOI: 10.1371/journal.pone.0203058] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
442 Murillo MM, Zelenay S, Nye E, Castellano E, Lassailly F, Stamp G, Downward J. RAS interaction with PI3K p110α is required for tumor-induced angiogenesis. J Clin Invest 2014;124:3601-11. [PMID: 25003191 DOI: 10.1172/JCI74134] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 5.9] [Reference Citation Analysis]
443 Tsutani Y, Miyata Y, Masuda T, Fujitaka K, Doi M, Awaya Y, Kuyama S, Kitaguchi S, Ueda K, Hattori N, Okada M. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. BMC Cancer 2018;18:1231. [PMID: 30526545 DOI: 10.1186/s12885-018-5146-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
444 Pili R, Carducci M, Brown P, Hurwitz H. An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. Invest New Drugs 2014;32:1258-68. [PMID: 25152243 DOI: 10.1007/s10637-014-0147-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
445 Corrales L, Nogueira A, Passiglia F, Listi A, Caglevic C, Giallombardo M, Raez L, Santos E, Rolfo C. Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib. Front Med (Lausanne) 2017;4:13. [PMID: 28293555 DOI: 10.3389/fmed.2017.00013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
446 Yanagisawa H, Sugimoto M, Miyashita T. Mathematical simulation of tumour angiogenesis: angiopoietin balance is a key factor in vessel growth and regression. Sci Rep 2021;11:419. [PMID: 33432093 DOI: 10.1038/s41598-020-79824-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
447 Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, Pietanza MC, Azzoli CG, Rizvi NA, Krug LM, Miller VA, Kris MG, Riely GJ. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013;8:346-51. [PMID: 23407558 DOI: 10.1097/JTO.0b013e31827e1f83] [Cited by in Crossref: 188] [Cited by in F6Publishing: 102] [Article Influence: 20.9] [Reference Citation Analysis]
448 Sarantopoulos J, Mita MM, Birrer MJ, Cranmer LD, Campos LT, Zhang X, Bristow P, Kaito H, Strout V, Camacho LH. Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. Target Oncol 2016;11:317-27. [PMID: 26507836 DOI: 10.1007/s11523-015-0394-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
449 Jao K, Labbe C, Leighl NB. Ready or not? Lung cancer diagnosis in 2015. Curr Oncol 2015;22:239-42. [PMID: 26300660 DOI: 10.3747/co.22.2647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
450 Lima AB, Macedo LT, Sasse AD. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2011;6:e22681. [PMID: 21829644 DOI: 10.1371/journal.pone.0022681] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.1] [Reference Citation Analysis]
451 Walleser S, Ray J, Bischoff H, Vergnenègre A, Rosery H, Chouaid C, Heigener D, de Castro Carpeño J, Tiseo M, Walzer S. Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe. Clinicoecon Outcomes Res 2012;4:269-75. [PMID: 23028234 DOI: 10.2147/CEOR.S31794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 0.2] [Reference Citation Analysis]
452 Wang J, Zhu C. Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis. Onco Targets Ther 2016;9:4737-46. [PMID: 27536135 DOI: 10.2147/OTT.S103184] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
453 Kravets S, Dahlberg SE. Interpretation of Results from Under-accruing Studies. Oncologist 2018;23:755-6. [PMID: 29739894 DOI: 10.1634/theoncologist.2018-0145] [Reference Citation Analysis]
454 Chen C, Jiang XL, Zhang CC, Li K. Correlation of genes associated with drug response to prognosis of large cell lung carcinoma. Chin J Cancer 2011;30:497-504. [PMID: 21718596 DOI: 10.5732/cjc.010.10503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
455 Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21:1381-1389. [PMID: 20538785 DOI: 10.1681/asn.2010020167] [Cited by in Crossref: 141] [Cited by in F6Publishing: 59] [Article Influence: 11.8] [Reference Citation Analysis]
456 Amedei A, Benagiano M, della Bella C, Niccolai E, D'Elios MM. Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol 2011;2011:437348. [PMID: 22253528 DOI: 10.1155/2011/437348] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
457 Behera M, Owonikoko TK, Chen Z, Kono SA, Khuri FR, Belani CP, Ramalingam SS. Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis. Lung Cancer 2012;77:331-8. [PMID: 22546678 DOI: 10.1016/j.lungcan.2012.03.019] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
458 Blais N, Corrales-Rodriguez L. Personalized choice of maintenance therapies in non-small-cell lung cancer. Curr Oncol 2012;19:S64-72. [PMID: 22787413 DOI: 10.3747/co.19.1068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
459 Navid F, Santana VM, Neel M, McCarville MB, Shulkin BL, Wu J, Billups CA, Mao S, Daryani VM, Stewart CF, Kunkel M, Smith W, Ward D, Pappo AS, Bahrami A, Loeb DM, Reikes Willert J, Rao BN, Daw NC. A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. Int J Cancer 2017;141:1469-77. [PMID: 28631382 DOI: 10.1002/ijc.30841] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
460 Ishii H, Azuma K, Yamada K, Matsuo N, Nakamura M, Tokito T, Kinoshita T, Hoshino T. Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy. BMJ Open Respir Res 2017;4:e000163. [PMID: 28123750 DOI: 10.1136/bmjresp-2016-000163] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
461 Pirker R. Milestones in the systemic treatment of lung cancer. Memo 2017;10:22-6. [PMID: 28367252 DOI: 10.1007/s12254-017-0313-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
462 Gkika E, Lenz S, Schimek-Jasch T, Waller CF, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, Tosch M, Hehr T, Eschmann SM, Bultel YP, Hass P, Fleckenstein J, Thieme AH, Stockinger M, Dieckmann K, Miederer M, Holl G, Rischke HC, Adebahr S, König J, Binder H, Grosu AL, Nestle U. Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer-A Secondary Analysis of the PET Plan Trial. Cancers (Basel) 2020;12:E3359. [PMID: 33202825 DOI: 10.3390/cancers12113359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
463 Zhou S, Yang Y, Yang Y, Tao H, Li D, Zhang J, Jiang G, Fang J. Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model. PLoS One 2013;8:e68589. [PMID: 23874680 DOI: 10.1371/journal.pone.0068589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
464 Hu W, Fang J, Nie J, Dai L, Zhang J, Chen X, Ma X, Tian G, Wu D, Han S, Han J, Wang Y, Long J. Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer. Medicine (Baltimore) 2016;95:e4183. [PMID: 27428214 DOI: 10.1097/MD.0000000000004183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
465 Tsironis G, Ziogas DC, Kyriazoglou A, Lykka M, Koutsoukos K, Bamias A, Dimopoulos MA. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore? Ann Transl Med. 2018;6:143. [PMID: 29862232 DOI: 10.21037/atm.2018.02.18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
466 Gendre DAJ, Ameti E, Karenovics W, Perriraz-Mayer N, Triponez F, Serre-Beinier V. Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052/484 spheroids. Oncotarget 2021;12:2375-87. [PMID: 34853659 DOI: 10.18632/oncotarget.28134] [Reference Citation Analysis]
467 Erinjeri JP, Fong AJ, Kemeny NE, Brown KT, Getrajdman GI, Solomon SB. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer. 2011;117:1296-1301. [PMID: 21381016 DOI: 10.1002/cncr.25573] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 4.9] [Reference Citation Analysis]
468 Cui C, Mao L, Chi Z, Si L, Sheng X, Kong Y, Li S, Lian B, Gu K, Tao M, Song X, Lin T, Ren X, Qin S, Guo J. A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther 2013;21:1456-63. [PMID: 23670576 DOI: 10.1038/mt.2013.79] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 6.6] [Reference Citation Analysis]
469 Conde E, Earl J, Crespo-Toro L, Blanco-Agudo C, Ramos-Muñoz E, Rodríguez-Serrano EM, Martínez Ávila JC, Salinas-Muñoz L, Serrano-Huertas S, Ferreiro R, Rodriguez-Garrote M, Sainz B Jr, Massuti B, Alfonso PG, Benavides M, Aranda E, García-Bermejo ML, Carrato A. Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study. Cancers (Basel) 2021;13:1710. [PMID: 33916610 DOI: 10.3390/cancers13071710] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
470 William WN Jr, Kies MS, Fossella FV, Liu DD, Gladish G, Tse WH, Lee JJ, Hong WK, Lippman SM, Kim ES. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer 2010;116:2401-8. [PMID: 20225327 DOI: 10.1002/cncr.24996] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
471 Hurwitz JL, Scullin P, Campbell L. Afatinib treatment in advanced non-small cell lung cancer. Lung Cancer (Auckl) 2011;2:47-57. [PMID: 28210118 DOI: 10.2147/LCTT.S16310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
472 Hall M, Gourley C, McNeish I, Ledermann J, Gore M, Jayson G, Perren T, Rustin G, Kaye S. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer 2013;108:250-8. [PMID: 23385789 DOI: 10.1038/bjc.2012.541] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
473 Tang H, Ma H, Peng F, Bao Y, Hu X, Wang J, Xu Y, Chen M. Prognostic performance of inflammation-based prognostic indices in locally advanced non-small-lung cancer treated with endostar and concurrent chemoradiotherapy. Mol Clin Oncol 2016;4:801-6. [PMID: 27123283 DOI: 10.3892/mco.2016.796] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
474 Neal JW. The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. Future Oncol 2010;6:1827-32. [PMID: 21142856 DOI: 10.2217/fon.10.156] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
475 Tarrar TA, Anwar MY, Ali MA, Saeed M, Rehman S, Bajwa SF, Ayub T, Javid H, Ali R, Irshad A, Aiman W. Current Status of Monoclonal Antibodies-Based Therapies in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials. Cureus. [DOI: 10.7759/cureus.22942] [Reference Citation Analysis]
476 Dong M, Wang R, Sun P, Zhang D, Zhang Z, Zhang J, Tse G, Zhong L. Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs. Oncol Lett 2021;21:315. [PMID: 33692847 DOI: 10.3892/ol.2021.12576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
477 Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009;15:6277-83. [PMID: 19773375 DOI: 10.1158/1078-0432.CCR-09-0717] [Cited by in Crossref: 68] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
478 Moudgil R, Yeh ET. Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond. Can J Cardiol 2016;32:863-870.e5. [PMID: 27117975 DOI: 10.1016/j.cjca.2016.01.027] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
479 Takayama K, Ichiki M, Tokunaga S, Inoue K, Kawasaki M, Uchino J, Nakanishi Y. Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer. Oncologist 2019;24:1420-e1010. [PMID: 31332099 DOI: 10.1634/theoncologist.2019-0513] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
480 Kohutek F, Stratena M, Rosik A, Tamasova M, Bystricky B. First-line treatment of nonsquamous NSCLC using gemcitabine: a retrospective study of real-life practice. Lung Cancer Manag 2016;5:123-30. [PMID: 30643556 DOI: 10.2217/lmt-2016-0011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
481 Afzal MZ, Dragnev K, Shirai K. A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer. J Thorac Dis 2018;10:3575-84. [PMID: 30069355 DOI: 10.21037/jtd.2018.06.08] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
482 Wong H, Tang YF, Yao TJ, Chiu J, Leung R, Chan P, Cheung TT, Chan AC, Pang RW, Poon R, Fan ST, Yau T. The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). Oncologist. 2011;16:1721-1728. [PMID: 22135121 DOI: 10.1634/theoncologist.2011-0192] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
483 Bhattacharya A. Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. Expert Opin Drug Deliv 2011;8:749-63. [PMID: 21473705 DOI: 10.1517/17425247.2011.571672] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
484 Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 2011;121:1313-28. [PMID: 21436589 DOI: 10.1172/JCI42405] [Cited by in Crossref: 108] [Cited by in F6Publishing: 57] [Article Influence: 9.8] [Reference Citation Analysis]
485 Fink DM, Steele MM, Hollingsworth MA. The lymphatic system and pancreatic cancer. Cancer Lett 2016;381:217-36. [PMID: 26742462 DOI: 10.1016/j.canlet.2015.11.048] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
486 Tian W, Cao C, Shu L, Wu F. Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer. Onco Targets Ther 2020;13:12113-29. [PMID: 33262610 DOI: 10.2147/OTT.S276150] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
487 Yin T, Wang G, He S, Shen G, Su C, Zhang Y, Wei X, Ye T, Li L, Yang S, Li D, Guo F, Mo Z, Wan Y, Ai P, Zhou X, Liu Y, Wang Y, Wei Y. Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway. J Biol Chem. 2016;291:26750-26761. [PMID: 27756837 DOI: 10.1074/jbc.m116.753236] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
488 Bayraktar S, Rocha-Lima CM. Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. World J Clin Oncol 2013; 4(2): 29-42 [PMID: 23696960 DOI: 10.5306/wjco.v4.i2.29] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
489 Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF; Chicago Phase II Consortium., PMH Phase II Consortium., California Phase II Consortium. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2008;110:49-55. [PMID: 18423560 DOI: 10.1016/j.ygyno.2008.02.009] [Cited by in Crossref: 114] [Cited by in F6Publishing: 101] [Article Influence: 8.1] [Reference Citation Analysis]
490 Manzo A, Carillio G, Montanino A, Costanzo R, Sandomenico C, Rocco G, Morabito A. Focus on Nintedanib in NSCLC and Other Tumors. Front Med (Lausanne) 2016;3:68. [PMID: 28066768 DOI: 10.3389/fmed.2016.00068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
491 Luengo-Gil G, Calvo MI, Martín-Villar E, Águila S, Bohdan N, Antón AI, Espín S, Ayala de la Peña F, Vicente V, Corral J, Quintanilla M, Martínez-Martínez I. Antithrombin controls tumor migration, invasion and angiogenesis by inhibition of enteropeptidase. Sci Rep 2016;6:27544. [PMID: 27270881 DOI: 10.1038/srep27544] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
492 Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34:2980-2987. [PMID: 27354485 DOI: 10.1200/jco.2016.66.9929] [Cited by in Crossref: 272] [Cited by in F6Publishing: 164] [Article Influence: 45.3] [Reference Citation Analysis]
493 Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One 2012;7:e31331. [PMID: 22355357 DOI: 10.1371/journal.pone.0031331] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
494 Hsiao KY, Wu YJ, Liu ZN, Chuang CW, Huang HH, Kuo SM. Anticancer Effects of Sinulariolide-Conjugated Hyaluronan Nanoparticles on Lung Adenocarcinoma Cells. Molecules 2016;21:297. [PMID: 26950100 DOI: 10.3390/molecules21030297] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
495 Vora N, Reckamp KL. Non-small cell lung cancer in the elderly: defining treatment options. Semin Oncol 2008;35:590-6. [PMID: 19027463 DOI: 10.1053/j.seminoncol.2008.08.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
496 Yehya AHS, Asif M, Petersen SH, Subramaniam AV, Kono K, Majid AMSA, Oon CE. Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis. Medicina (Kaunas) 2018;54:E8. [PMID: 30344239 DOI: 10.3390/medicina54010008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
497 Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res. 2009;15:3484-3494. [PMID: 19447865 DOI: 10.1158/1078-0432.ccr-08-2904] [Cited by in Crossref: 198] [Cited by in F6Publishing: 99] [Article Influence: 15.2] [Reference Citation Analysis]
498 Xu Z, Li T, Hu X, Hao X, Xing P, Li J. Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC). Thorac Cancer 2021;12:2360-8. [PMID: 34268872 DOI: 10.1111/1759-7714.14078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
499 Maj E, Filip-Psurska B, Milczarek M, Psurski M, Kutner A, Wietrzyk J. Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model. Int J Oncol 2018;52:337-66. [PMID: 29345296 DOI: 10.3892/ijo.2017.4228] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
500 Ploner F. [NSCLC: update on second line therapy following ASCO 2007]. Wien Med Wochenschr 2007;157:540-4. [PMID: 18157591 DOI: 10.1007/s10354-007-0481-z] [Reference Citation Analysis]
501 Hwang IG, Kwon M, Kim JW, Kim SH, Lee YG, Kim JY, Koh SJ, Ko YH, Shin SH, Hong S, Kim TY, Kim SY, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Lee KH, Bae SH, Koo DH, Kim JH, Woo IS. Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. Cancers (Basel) 2021;13:331. [PMID: 33477423 DOI: 10.3390/cancers13020331] [Reference Citation Analysis]
502 Kärrlander M, Lindberg N, Olofsson T, Kastemar M, Olsson AK, Uhrbom L. Histidine-rich glycoprotein can prevent development of mouse experimental glioblastoma. PLoS One 2009;4:e8536. [PMID: 20046875 DOI: 10.1371/journal.pone.0008536] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
503 Nakamura H, Satoh H, Kaburagi T, Nishimura Y, Shinohara Y, Inagaki M, Endo T, Saito T, Hayashihara K, Hizawa N, Kurishima K, Nawa T, Kagohashi K, Kishi K, Ishikawa H, Ichimura H, Hashimoto T, Sato Y, Sakai M, Kamiyama K, Matsumura T, Unoura K, Furukawa K. Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group. Med Oncol 2012;29:3202-6. [PMID: 23117478 DOI: 10.1007/s12032-012-0318-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
504 Wang R, Li K, Pi J, Meng L, Zhu M. Cavitation and fatal hemoptysis after immunotherapy for advanced lung adenocarcinoma: A case report. Thorac Cancer 2020;11:2727-30. [PMID: 32691523 DOI: 10.1111/1759-7714.13578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
505 Pranchevicius MC, Vieira TR. Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering. Bioengineered 2013;4:305-12. [PMID: 23644447 DOI: 10.4161/bioe.24666] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
506 Basu B, Eisen T. Perspectives in drug development for metastatic renal cell cancer. Target Oncol 2010;5:139-56. [PMID: 20689997 DOI: 10.1007/s11523-010-0149-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
507 Jazieh AR, Al Kattan K, Bamousa A, Al Olayan A, Abdelwarith A, Ansari J, Al Twairqi A, Al Fayea T, Al Saleh K, Al Husaini H, Abdelhafiez N, Mahrous M, Faris M, Al Omair A, Hebshi A, Al Shehri S, Al Dayel F, Bamefleh H, Khalbuss W, Al Ghanem S, Loutfi S, Khankan A, Al Rujaib M, Al Ghamdi M, Ibrahim N, Swied A, Al Kayait M, Datario M; AR Jazieh on Behalf of Saudi Lung Cancer Guidelines Association, Saudi Lung Cancer Guidelines Members. Saudi lung cancer management guidelines 2017. Ann Thorac Med 2017;12:221-46. [PMID: 29118855 DOI: 10.4103/atm.ATM_92_17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
508 Wurz GT, Kao CJ, DeGregorio MW. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol 2016;8:4-31. [PMID: 26753003 DOI: 10.1177/1758834015615514] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
509 Villaflor VM, Salgia R. Targeted agents in non-small cell lung cancer therapy: What is there on the horizon? J Carcinog 2013;12:7. [PMID: 23599689 DOI: 10.4103/1477-3163.109253] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
510 Lu S, Yu YF. Maintenance Therapy for NSCLC: Consensus and Controversy. Chin J Cancer Res 2011;23:254-8. [PMID: 23359213 DOI: 10.1007/s11670-011-0254-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
511 Bertaglia V, Vallone S, Pacchiana MV, Novello S. Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey. Lung Cancer Manag 2017;6:93-107. [PMID: 30643575 DOI: 10.2217/lmt-2017-0011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
512 Gaughan EM, Costa DB. Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol 2011;3:113-25. [PMID: 21904575 DOI: 10.1177/1758834010397569] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 6.0] [Reference Citation Analysis]
513 Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology 2015;4:e985940. [PMID: 25949870 DOI: 10.4161/2162402X.2014.985940] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
514 Yang JJ, Huang C, Chen GY, Song Y, Cheng Y, Yan HH, Zhou Q, Wu YL. A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung. BMC Cancer 2014;14:684. [PMID: 25239521 DOI: 10.1186/1471-2407-14-684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
515 Qi WX, Tang LN, Shen Z, Yao Y. Treatment-related mortality with aflibercept in cancer patients: a meta-analysis. Eur J Clin Pharmacol 2014;70:461-7. [PMID: 24390630 DOI: 10.1007/s00228-013-1633-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
516 Chen HJ, Yang JJ, Fang LY, Huang MM, Yan HH, Zhang XC, Xu CR, Wu YL. Feasibility of computed tomography-guided core needle biopsy in producing state-of-the-art clinical management in Chinese lung cancer. Thorac Cancer 2014;5:155-61. [PMID: 26766993 DOI: 10.1111/1759-7714.12076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
517 Okabe N, Ezaki J, Yamaura T, Muto S, Osugi J, Tamura H, Imai J, Ito E, Yanagisawa Y, Honma R, Gotoh M, Watanabe S, Waguri S, Suzuki H. FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma. Int J Oncol 2015;46:999-1006. [PMID: 25586059 DOI: 10.3892/ijo.2015.2817] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
518 Cramer-van der Welle CM, Peters BJM, Schramel FMNH, Klungel OH, Groen HJM, van de Garde EMW; Santeon NSCLC Study Group., Santeon NSCLC study group. Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer. Eur Respir J 2018;52:1801100. [PMID: 30487206 DOI: 10.1183/13993003.01100-2018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
519 Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008;14:7068-73. [PMID: 18981004 DOI: 10.1158/1078-0432.CCR-08-0260] [Cited by in Crossref: 133] [Cited by in F6Publishing: 56] [Article Influence: 9.5] [Reference Citation Analysis]
520 Zhou M, Chen X, Zhang H, Xia L, Tong X, Zou L, Hao R, Pan J, Zhao X, Chen D, Song Y, Qi Y, Tang L, Liu Z, Gao R, Shi Y, Yang Z. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Commun (Lond) 2019;39:36. [PMID: 31221221 DOI: 10.1186/s40880-019-0383-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
521 Hsu MC, Pan MR, Hung WC. Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3. Cells 2019;8:E270. [PMID: 30901976 DOI: 10.3390/cells8030270] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
522 Li Z, Wei J, Cao H, Song M, Zhang Y, Jin Y. A predictive web-based nomogram for the early death of patients with lung adenocarcinoma and bone metastasis: a population-based study. J Int Med Res 2021;49:3000605211047771. [PMID: 34590874 DOI: 10.1177/03000605211047771] [Reference Citation Analysis]
523 Bialk P, Wang Y, Banas K, Kmiec EB. Functional Gene Knockout of NRF2 Increases Chemosensitivity of Human Lung Cancer A549 Cells In Vitro and in a Xenograft Mouse Model. Mol Ther Oncolytics 2018;11:75-89. [PMID: 30505938 DOI: 10.1016/j.omto.2018.10.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
524 Javle M, Yu J, Garrett C, Pande A, Kuvshinoff B, Litwin A, Phelan J 3rd, Gibbs J, Iyer R. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer 2009;100:1842-5. [PMID: 19491904 DOI: 10.1038/sj.bjc.6605099] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
525 Castro MG, Candolfi M, Kroeger K, King GD, Curtin JF, Yagiz K, Mineharu Y, Assi H, Wibowo M, Ghulam Muhammad AK, Foulad D, Puntel M, Lowenstein PR. Gene therapy and targeted toxins for glioma. Curr Gene Ther 2011;11:155-80. [PMID: 21453286 DOI: 10.2174/156652311795684722] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
526 Gyanchandani R, Kim S. Predictive biomarkers to anti-VEGF therapy: progress toward an elusive goal. Clin Cancer Res 2013;19:755-7. [PMID: 23386694 DOI: 10.1158/1078-0432.CCR-12-3585] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
527 Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, Bossi P, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS;  Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer; 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24:4057-4074. [PMID: 27344327 DOI: 10.1007/s00520-016-3310-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
528 Rivalland G, Scott AM, John T. Standard of care in immunotherapy trials: Challenges and considerations. Hum Vaccin Immunother 2017;13:2164-78. [PMID: 28267397 DOI: 10.1080/21645515.2016.1277845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
529 Rosen LS, Gordon MS, Robert F, Matei DE. Endoglin for targeted cancer treatment. Curr Oncol Rep. 2014;16:365. [PMID: 24445497 DOI: 10.1007/s11912-013-0365-x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 8.0] [Reference Citation Analysis]
530 Szasz A. Current status of oncothermia therapy for lung cancer. Korean J Thorac Cardiovasc Surg 2014;47:77-93. [PMID: 24782955 DOI: 10.5090/kjtcs.2014.47.2.77] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
531 Finkelmeier F, You SJ, Waidmann O, Wolff R, Zeuzem S, Bähr O, Trojan J. Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis. J Gastrointest Cancer 2016;47:82-8. [PMID: 26714801 DOI: 10.1007/s12029-015-9795-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
532 Sumi T, Hirai S, Yamaguchi M, Tanaka Y, Tada M, Yamada G, Hasegawa T, Miyagi Y, Niki T, Watanabe A, Takahashi H, Sakuma Y. Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas. Int J Oncol 2018;53:33-46. [PMID: 29658609 DOI: 10.3892/ijo.2018.4365] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
533 Powell SF, Dudek AZ. Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed. Pharmgenomics Pers Med 2009;2:21-37. [PMID: 23226032 DOI: 10.2147/pgpm.s3977] [Reference Citation Analysis]
534 Kerbel RS. Reappraising antiangiogenic therapy for breast cancer. Breast 2011;20 Suppl 3:S56-60. [PMID: 22015294 DOI: 10.1016/S0960-9776(11)70295-8] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
535 Eskander RN, Randall LM. Bevacizumab in the treatment of ovarian cancer. Biologics 2011;5:1-5. [PMID: 21383911 DOI: 10.2147/BTT.S13071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 0.2] [Reference Citation Analysis]
536 Riely GJ, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, Senturk E, Azzoli CG, Brahmer JR, Sirotnak FM. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:264-270. [PMID: 19047285 DOI: 10.1200/jco.2008.17.4656] [Cited by in Crossref: 40] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
537 Flaherty KT, Hamilton BK, Rosen MA, Amaravadi RK, Schuchter LM, Gallagher M, Chen H, Sehgal C, O'Dwyer PJ. Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. Oncologist 2015;20:952-9. [PMID: 26084808 DOI: 10.1634/theoncologist.2015-0108] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
538 Kader YA, Le Chevalier T, El-Nahas T, Sakr A. Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation. Onco Targets Ther 2013;6:803-9. [PMID: 23836994 DOI: 10.2147/OTT.S45906] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
539 Padmanabhan RK, Somasundar VH, Griffith SD, Zhu J, Samoyedny D, Tan KS, Hu J, Liao X, Carin L, Yoon SS, Flaherty KT, Dipaola RS, Heitjan DF, Lal P, Feldman MD, Roysam B, Lee WM. An active learning approach for rapid characterization of endothelial cells in human tumors. PLoS One 2014;9:e90495. [PMID: 24603893 DOI: 10.1371/journal.pone.0090495] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
540 Flaig TW, Kim FJ, La Rosa FG, Breaker K, Schoen J, Russ PD. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs. 2009;27:83-87. [PMID: 18563296 DOI: 10.1007/s10637-008-9146-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
541 Palka KT, Slebos RJ, Chung CH. Update on molecular diagnostic tests in head and neck cancer. Semin Oncol 2008;35:198-210. [PMID: 18544435 DOI: 10.1053/j.seminoncol.2008.03.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
542 Fennell DA, Swanton C. Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer. EPMA J 2012;3:6. [PMID: 22738201 DOI: 10.1186/1878-5085-3-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
543 An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB, Jiang YY. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 2010;66:813-21. [PMID: 20401474 DOI: 10.1007/s00228-010-0815-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
544 Simone CB 2nd, Burri SH, Heinzerling JH. Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. Transl Lung Cancer Res 2015;4:545-52. [PMID: 26629423 DOI: 10.3978/j.issn.2218-6751.2015.10.05] [Cited by in F6Publishing: 32] [Reference Citation Analysis]
545 Qu JT, Wang M, He HL, Tang Y, Ye XJ. The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review. J Cancer Res Clin Oncol 2012;138:819-25. [PMID: 22274866 DOI: 10.1007/s00432-012-1149-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
546 Rahbari NN, Schmidt T, Falk CS, Hinz U, Herber M, Bork U, Büchler MW, Weitz J, Koch M. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer 2011;11:286. [PMID: 21729304 DOI: 10.1186/1471-2407-11-286] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
547 Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res 2012;18:4820-9. [PMID: 22767667 DOI: 10.1158/1078-0432.CCR-12-0098] [Cited by in Crossref: 121] [Cited by in F6Publishing: 90] [Article Influence: 12.1] [Reference Citation Analysis]
548 Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res 2015;7:133-43. [PMID: 26082660 DOI: 10.2147/CMAR.S77400] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 6.1] [Reference Citation Analysis]
549 Shibata Y, Kobayashi N, Sato T, Nakashima K, Kaneko T. The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer. Thorac Cancer 2020;11:1258-64. [PMID: 32163231 DOI: 10.1111/1759-7714.13387] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
550 Gomez DR, Niibe Y, Chang JY. Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer. Pulm Med 2012;2012:396592. [PMID: 22900169 DOI: 10.1155/2012/396592] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
551 Dean E, Middleton MR, Pwint T, Swaisland H, Carmichael J, Goodege-Kunwar P, Ranson M. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer. 2012;106:468-474. [PMID: 22223088 DOI: 10.1038/bjc.2011.555] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 9.2] [Reference Citation Analysis]
552 Song ZZ, Zhao LF, Zuo J, Fan ZS, Wang L, Wang YD. Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism. Onco Targets Ther 2020;13:603-13. [PMID: 32021302 DOI: 10.2147/OTT.S222985] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
553 Zhao C, Sun H, Yang Y, Dai X. [Pemetrexed combined DDP in the treatment of advanced non-small cell lung cancer: a case report and literature review]. Zhongguo Fei Ai Za Zhi 2010;13:755-8. [PMID: 20673495 DOI: 10.3779/j.issn.1009-3419.2010.07.18] [Reference Citation Analysis]
554 Saffra N, Reinherz B. Systemic bevacizumab for simultaneous treatment of cancer and choroidal neovascularisation. BMJ Case Rep 2014;2014:bcr2014204500. [PMID: 24825559 DOI: 10.1136/bcr-2014-204500] [Reference Citation Analysis]
555 Meng X, Zhao R, Wu S, Shen G, Ding L, Sun B, Wang J. Efficacy of repeated low-dose bevacizumab treatment with long-dosing interval for radiation-induced brain necrosis: A case report. Cancer Biol Ther 2017;18:63-6. [PMID: 28152324 DOI: 10.1080/15384047.2016.1276127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
556 Lassoued W, Murphy D, Tsai J, Oueslati R, Thurston G, Lee WM. Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. Cancer Biol Ther 2010;10:1326-33. [PMID: 21079419 DOI: 10.4161/cbt.10.12.14009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
557 Lupo G, Caporarello N, Olivieri M, Cristaldi M, Motta C, Bramanti V, Avola R, Salmeri M, Nicoletti F, Anfuso CD. Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine. Front Pharmacol. 2016;7:519. [PMID: 28111549 DOI: 10.3389/fphar.2016.00519] [Cited by in Crossref: 27] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
558 Bender RJ, Mac Gabhann F. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis. BMC Syst Biol 2015;9:55. [PMID: 26341082 DOI: 10.1186/s12918-015-0201-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
559 Coate LE, Shepherd FA. Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes. Ther Adv Med Oncol 2011;3:139-57. [PMID: 21904577 DOI: 10.1177/1758834011399306] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
560 Desoubeaux G, Reichert JM, Sleeman M, Reckamp KL, Ryffel B, Adamczewski JP, Sweeney TD, Vanbever R, Diot P, Owen CA, Page C, Lerondel S, Le Pape A, Heuze-Vourc'h N. Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France. MAbs 2016;8:999-1009. [PMID: 27266390 DOI: 10.1080/19420862.2016.1196521] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
561 Hasenöhrl N. [Bevacizumab in the first-line therapy of advanced NSCLC]. Wien Med Wochenschr 2007;157:576-8. [PMID: 18157597 DOI: 10.1007/s10354-007-0491-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
562 Ayeni O, Robinson A. Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed? Curr Oncol 2009;16:21-5. [PMID: 19526081 DOI: 10.3747/co.v16i3.302] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
563 Oka S, Shinohara S, Kuwata T, Takenaka M, Chikaishi Y, Hirai A, Ichiki Y, Shimajiri S, Aoki T, Tanaka F. The major thoracic vascular invasion of lung cancer. Ann Med Surg (Lond) 2017;20:13-8. [PMID: 28702181 DOI: 10.1016/j.amsu.2017.06.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
564 Ruan J, Hajjar K, Rafii S, Leonard JP. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol 2009;20:413-24. [PMID: 19088170 DOI: 10.1093/annonc/mdn666] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 4.9] [Reference Citation Analysis]
565 Sorrentino C, Miele L, Porta A, Pinto A, Morello S. Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model. Oncotarget 2015;6:27478-89. [PMID: 26317647 DOI: 10.18632/oncotarget.4393] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 9.7] [Reference Citation Analysis]
566 Morgensztern D. KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49. J Thorac Dis 2019;11:S1963-5. [PMID: 31632798 DOI: 10.21037/jtd.2019.07.80] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
567 Ikeda S, Kato T, Ogura T, Sekine A, Oda T, Masuda N, Igawa S, Katono K, Otani S, Yamada K, Saito H, Kondo T, Hosomi Y, Nakahara Y, Nishikawa M, Utumi K, Misumi Y, Yamanaka T, Sakamaki K, Okamoto H. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016. BMC Cancer 2018;18:241. [PMID: 29499653 DOI: 10.1186/s12885-018-4150-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
568 Miao L, Guo S, Lin CM, Liu Q, Huang L. Nanoformulations for combination or cascade anticancer therapy. Adv Drug Deliv Rev 2017;115:3-22. [PMID: 28624477 DOI: 10.1016/j.addr.2017.06.003] [Cited by in Crossref: 99] [Cited by in F6Publishing: 86] [Article Influence: 19.8] [Reference Citation Analysis]
569 Okita Y, Nonaka M, Umehara T, Kanemura Y, Kodama Y, Mano M, Nakajima S. Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report. Oncol Lett 2015;9:1885-8. [PMID: 25789061 DOI: 10.3892/ol.2015.2940] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
570 Pugliese SB, Neal JW, Kwong BY. Management of Dermatologic Complications of Lung Cancer Therapies. Curr Treat Options Oncol 2015;16:50. [PMID: 26338208 DOI: 10.1007/s11864-015-0368-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
571 Katz Y, Somer RA. Maintenance therapy for metastatic non-small-cell lung cancer - the role of pemetrexed. Lung Cancer (Auckl) 2010;1:1-7. [PMID: 28210102 DOI: 10.2147/lctt.s7105] [Reference Citation Analysis]
572 Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak EL, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, Morrow M, Arnott J, Bray MR, Sidor C, Messersmith W, Shapiro GI. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2011;17:849-60. [PMID: 21131552 DOI: 10.1158/1078-0432.CCR-10-2144] [Cited by in Crossref: 50] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
573 Salmaggi A, Gaviani P, Botturi A, Lamperti E, Simonetti G, Ferrari D, Silvani A. Bevacizumab at recurrence in high-grade glioma. Neurol Sci 2011;32 Suppl 2:S251-3. [PMID: 21987287 DOI: 10.1007/s10072-011-0799-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
574 Conde E, Angulo B, Izquierdo E, Paz-Ares L, Belda-Iniesta C, Hidalgo M, López-Ríos F. Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers. Clin Transl Oncol 2013;15:503-8. [PMID: 23359174 DOI: 10.1007/s12094-012-0983-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
575 Wang Z, Zhou PU, Li G. Bevacizumab to combat EGFR-TKI resistance in a patient with advanced non-small cell lung cancer harboring an EGFR mutation: A case report. Oncol Lett 2016;12:356-60. [PMID: 27347151 DOI: 10.3892/ol.2016.4574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
576 Schulze AB, Schmidt LH, Heitkötter B, Huss S, Mohr M, Marra A, Hillejan L, Görlich D, Barth PJ, Rehkämper J, Evers G. Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLC. Thorac Cancer 2020;11:120-9. [PMID: 31760702 DOI: 10.1111/1759-7714.13248] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
577 Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G. [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. Zhongguo Fei Ai Za Zhi 2010;13:171-89. [PMID: 20681066 DOI: 10.3779/j.issn.1009-3419.2010.03.15] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
578 Goel G, Sun W. Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014;33:445-57. [PMID: 25189717 DOI: 10.5732/cjc.014.10123] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
579 Huang K. Global trends of researches on bone metastasis: A bibliometric and visualization study. Medicine (Baltimore) 2022;101:e28761. [PMID: 35147101 DOI: 10.1097/MD.0000000000028761] [Reference Citation Analysis]
580 Villaruz LC, Socinski MA. Personalized therapy for non-small cell lung cancer: which drug for which patient? Semin Thorac Cardiovasc Surg 2011;23:281-90. [PMID: 22443647 DOI: 10.1053/j.semtcvs.2012.01.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
581 Huang H, Zheng Y, Zhu J, Zhang J, Chen H, Chen X. An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One 2014;9:e89960. [PMID: 24599121 DOI: 10.1371/journal.pone.0089960] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
582 Wu D, Nie J, Dai L, Hu W, Zhang J, Chen X, Ma X, Tian G, Han J, Han S, Long J, Wang Y, Zhang Z, Fang J. Salvage treatment with anlotinib for advanced non-small cell lung cancer. Thorac Cancer 2019;10:1590-6. [PMID: 31183998 DOI: 10.1111/1759-7714.13120] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
583 Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE. Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis. Lung Cancer 2016;98:106-13. [PMID: 27393515 DOI: 10.1016/j.lungcan.2016.05.029] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
584 Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig 2010;30:229-41. [PMID: 20225906 DOI: 10.2165/11532260-000000000-00000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
585 Wu G, Zhu Z, Yang Z, He M, Ren K, Dong Y, Xue Q. A Hypoxia-Related Signature for Predicting Prognosis, Cellular Processes, Immune Microenvironment and Targeted Compounds in Lung Squamous Cell Carcinoma. IJGM 2022;Volume 15:3991-4006. [DOI: 10.2147/ijgm.s344228] [Reference Citation Analysis]
586 Wu CJ, Cai T, Rikova K, Merberg D, Kasif S, Steffen M. A predictive phosphorylation signature of lung cancer. PLoS One 2009;4:e7994. [PMID: 19946374 DOI: 10.1371/journal.pone.0007994] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
587 Weiss JM, Villaruz LC, O'Brien J, Ivanova A, Lee C, Olson JG, Pollack G, Gorman R, Socinski MA, Stinchombe TE. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer. Clin Lung Cancer 2016;17:128-32. [PMID: 26774201 DOI: 10.1016/j.cllc.2015.12.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
588 Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol 2010;7:401-14. [PMID: 20551945 DOI: 10.1038/nrclinonc.2010.64] [Cited by in Crossref: 174] [Cited by in F6Publishing: 160] [Article Influence: 14.5] [Reference Citation Analysis]
589 He M, Xue Y. MicroRNA-148a suppresses proliferation and invasion potential of non-small cell lung carcinomas via regulation of STAT3. Onco Targets Ther 2017;10:1353-61. [PMID: 28280370 DOI: 10.2147/OTT.S123518] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
590 Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 2020;77:1745-70. [PMID: 31690961 DOI: 10.1007/s00018-019-03351-7] [Cited by in Crossref: 157] [Cited by in F6Publishing: 151] [Article Influence: 52.3] [Reference Citation Analysis]
591 Souza FF, Smith A, Araujo C, Jagannathan J, Johnston C, O'Regan K, Shinagare A, Ramaiya N. New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know. Cancer Imaging 2014;14:26. [PMID: 25608887 DOI: 10.1186/1470-7330-14-26] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
592 Vergnenègre A, Borget I, Chouaid C. Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents. Clinicoecon Outcomes Res 2013;5:137-41. [PMID: 23630426 DOI: 10.2147/CEOR.S30670] [Reference Citation Analysis]
593 Zhou Y, He M, Li R, Peng Y, Li F, Li S, Yang M. The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Biomed Res Int 2021;2021:5537899. [PMID: 34532503 DOI: 10.1155/2021/5537899] [Reference Citation Analysis]
594 Shishido SN, Carlsson A, Nieva J, Bethel K, Hicks JB, Bazhenova L, Kuhn P. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. J Transl Med 2019;17:294. [PMID: 31462312 DOI: 10.1186/s12967-019-2035-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
595 Liu FT, Ou-Yang X, Zhang GP, Luo HL. Nanobodies for targeted treatment of gastric cancer. Shijie Huaren Xiaohua Zazhi 2015; 23(23): 3714-3719 [DOI: 10.11569/wcjd.v23.i23.3714] [Reference Citation Analysis]
596 Xing P, Mu Y, Wang Y, Hao X, Zhu Y, Hu X, Wang H, Liu P, Lin L, Wang Z, Li J. Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer. Thorac Cancer 2018;9:1716-24. [PMID: 30324773 DOI: 10.1111/1759-7714.12886] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
597 Lee SH, Jeong D, Han YS, Baek MJ. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res 2015;89:1-8. [PMID: 26131438 DOI: 10.4174/astr.2015.89.1.1] [Cited by in Crossref: 105] [Cited by in F6Publishing: 87] [Article Influence: 15.0] [Reference Citation Analysis]
598 Pastina P, Nardone V, Croci S, Battaglia G, Vanni F, Bellan C, Barbarino M, Ricci V, Costantini S, Capone F, Botta C, Zarone MR, Misso G, Boccellino M, Caraglia M, Giordano A, Paladini P, Tassone P, Tagliaferri P, Cusi MG, Pirtoli L, Correale P. Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients. J Thorac Dis 2017;9:3123-31. [PMID: 29221287 DOI: 10.21037/jtd.2017.08.68] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
599 Pal SK, Bergerot PG, Figlin RA. Tivozanib: current status and future directions in the treatment of solid tumors. Expert Opin Investig Drugs 2012;21:1851-9. [PMID: 23013465 DOI: 10.1517/13543784.2012.733695] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
600 Wozniak AJ, Moon J, Thomas CR Jr, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara DR. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 2015;16:340-7. [PMID: 25703100 DOI: 10.1016/j.cllc.2014.12.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
601 Liu X. [The question and analysis about maintenance therapy in advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2014;17:289-93. [PMID: 24758902 DOI: 10.3779/j.issn.1009-3419.2014.04.02] [Reference Citation Analysis]
602 Konno H, Yamamoto M, Ohta M. Recent concepts of antiangiogenic therapy. Surg Today 2010;40:494-500. [PMID: 20496129 DOI: 10.1007/s00595-009-4150-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
603 Morales La Madrid A, Campbell N, Smith S, Cohn SL, Salgia R. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol 2012;7:199-210. [PMID: 22968692 DOI: 10.1007/s11523-012-0227-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
604 Grueso E, Sánchez-Martínez C, Calvo-López T, de Miguel FJ, Blanco-Menéndez N, Fernandez-Estevez M, Elizalde M, Sanchez J, Kourani O, Martin D, Tato A, Guerra M, Andrés G, Almendral JM. Antiangiogenic Vascular Endothelial Growth Factor-Blocking Peptides Displayed on the Capsid of an Infectious Oncolytic Parvovirus: Assembly and Immune Interactions. J Virol 2019;93:e00798-19. [PMID: 31315994 DOI: 10.1128/JVI.00798-19] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
605 Sundaram S, Trivedi R, Durairaj C, Ramesh R, Ambati BK, Kompella UB. Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res 2009;15:7299-308. [PMID: 19920099 DOI: 10.1158/1078-0432.CCR-09-1745] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
606 Algazi AP, Cha E, Ortiz-Urda SM, McCalmont T, Bastian BC, Hwang J, Pampaloni MH, Behr S, Chong K, Cortez B, Quiroz A, Coakley F, Liu S, Daud AI. The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. Br J Cancer 2015;112:1326-31. [PMID: 25867272 DOI: 10.1038/bjc.2014.541] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
607 Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. J Natl Cancer Inst 2015;107:djv002. [PMID: 25667420 DOI: 10.1093/jnci/djv002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 54] [Article Influence: 6.9] [Reference Citation Analysis]
608 Buess M, Rajski M, Vogel-Durrer BM, Herrmann R, Rochlitz C. Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer. Neoplasia 2009;11:987-1002. [PMID: 19794958 DOI: 10.1593/neo.09670] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
609 Weberpals J, Jansen L, Haefeli WE, Hoffmeister M, Wolkewitz M, Herk-Sukel MPPV, Vissers PAJ, Brenner H. Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study. Sci Rep 2017;7:2911. [PMID: 28588274 DOI: 10.1038/s41598-017-02913-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
610 Thatcher N, Heighway J. Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer. Oncologist 2010;15:1034-42. [PMID: 20930098 DOI: 10.1634/theoncologist.2009-0292] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
611 Algahtani M, Natarajan U, Alhazzani K, Alaseem A, Rathinavelu A. Evaluation of Anti-angiogenic Agent F16 for Targeting Glioblastoma Xenograft Tumors. Cancer Genetics 2022. [DOI: 10.1016/j.cancergen.2022.04.001] [Reference Citation Analysis]
612 Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol 2012;7:1361-8. [PMID: 22843087 DOI: 10.1097/JTO.0b013e318260e106] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
613 Hu H, Pan Y, Li Y, Wang L, Wang R, Zhang Y, Li H, Ye T, Zhang Y, Luo X, Shao L, Sun Z, Cai D, Xu J, Lu Q, Deng Y, Shen L, Ji H, Sun Y, Chen H. Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. Onco Targets Ther 2014;7:1423-37. [PMID: 25152623 DOI: 10.2147/OTT.S58900] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
614 Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, El-Rayes BF, Flowers CR. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol 2015;33:1112-8. [PMID: 25691669 DOI: 10.1200/JCO.2014.58.4904] [Cited by in Crossref: 97] [Cited by in F6Publishing: 49] [Article Influence: 13.9] [Reference Citation Analysis]
615 Mohile SG, Hardt M, Tew W, Owusu C, Klepin H, Gross C, Gajra A, Lichtman SM, Feng T, Togawa K, Ramani R, Katheria V, Hansen K, Hurria A; Cancer and Aging Research Group. Toxicity of bevacizumab in combination with chemotherapy in older patients. Oncologist 2013;18:408-14. [PMID: 23576485 DOI: 10.1634/theoncologist.2012-0351] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
616 Grossi F, Kubota K, Cappuzzo F, de Marinis F, Gridelli C, Aita M, Douillard JY. Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. Oncologist. 2010;15:1102-1112. [PMID: 20930102 DOI: 10.1634/theoncologist.2010-0322] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
617 Cheng CL, Hou HA, Jhuang JY, Lin CW, Chen CY, Tang JL, Chou WC, Tseng MH, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF. High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes. Br J Cancer 2011;105:975-82. [PMID: 21878936 DOI: 10.1038/bjc.2011.340] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
618 Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): Results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18:31-41. [PMID: 27932067 DOI: 10.1016/s1470-2045(16)30624-6] [Cited by in Crossref: 492] [Cited by in F6Publishing: 282] [Article Influence: 82.0] [Reference Citation Analysis]
619 Bonanno L, Pavan A, Pasello G, Indraccolo S. Editorial on "The AvaALL Randomized Clinical Trial". J Thorac Dis 2019;11:S1237-40. [PMID: 31245096 DOI: 10.21037/jtd.2019.02.62] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
620 Melosky B. Shifting the paradigm for maintenance therapy in advanced non-small-cell lung cancer. Lung Cancer (Auckl) 2010;1:53-62. [PMID: 28210106 DOI: 10.2147/lctt.s5909] [Reference Citation Analysis]
621 Zhou D, Gulinuer W, Zhu N. Chemotherapy in combination with pembrolizumab and antiangiogenesis in young patients with advanced primary pulmonary mucinous adenocarcinoma: Two case reports. Sci Prog 2021;104:368504211061971. [PMID: 34842490 DOI: 10.1177/00368504211061971] [Reference Citation Analysis]
622 Carcereny Costa E, Viñolas Segarra N, Gascón Vilaplana P. Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC). Clin Transl Oncol 2008;10:198-203. [PMID: 18411192 DOI: 10.1007/s12094-008-0182-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
623 Lourdes LS, Jalal SI, Hanna N. Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer. Oncologist 2015;20:975-8. [PMID: 26268739 DOI: 10.1634/theoncologist.2015-0182] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
624 du Bois A, Vergote I, Wimberger P, Ray-Coquard I, Harter P, Curtis LB, Mitrica I. Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group. Br J Cancer 2012;106:629-32. [PMID: 22240783 DOI: 10.1038/bjc.2011.608] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
625 Liu Y, Li HM, Wang R. Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis. Front Med (Lausanne) 2021;8:616380. [PMID: 34277647 DOI: 10.3389/fmed.2021.616380] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
626 Daum S, Hagen H, Naismith E, Wolf D, Pircher A. The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer - New Combinational Approaches and Strategies of Neovessel Inhibition. Front Cell Dev Biol 2020;8:610903. [PMID: 33469537 DOI: 10.3389/fcell.2020.610903] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
627 Lee JH, Kim B, Ko S, Kim W. Analgesic Effect of SH003 and Trichosanthes kirilowii Maximowicz in Paclitaxel-Induced Neuropathic Pain in Mice. CIMB 2022;44:718-30. [DOI: 10.3390/cimb44020050] [Reference Citation Analysis]
628 Brown L, Wan H. Desmoglein 3: a help or a hindrance in cancer progression? Cancers (Basel) 2015;7:266-86. [PMID: 25629808 DOI: 10.3390/cancers7010266] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
629 Kinoshita T, Terai H, Yaguchi T. Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. Life (Basel) 2021;11:1029. [PMID: 34685400 DOI: 10.3390/life11101029] [Reference Citation Analysis]
630 O'Neill CB, Atoria CL, O'Reilly EM, Henman MC, Bach PB, Elkin EB, O'Neill CB, Atoria CL, O'Reilly EM, Henman MC, Bach PB, Elkin EB. ReCAP: Hospitalizations in Older Adults With Advanced Cancer: The Role of Chemotherapy. J Oncol Pract 2016;12:151-2; e138-48. [PMID: 26869655 DOI: 10.1200/JOP.2015.004812] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
631 Filosso PL, Sandri A, Oliaro A, Filippi AR, Cassinis MC, Ricardi U, Lausi PO, Asioli S, Ruffini E. Emerging treatment options in the management of non-small cell lung cancer. Lung Cancer (Auckl) 2011;2:11-28. [PMID: 28210115 DOI: 10.2147/LCTT.S8618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
632 Wang Z, Zhang H, Zhou C, Long X, Guan R, Yang N, Zhang Y. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer. Cancer Med 2019;8:1434-41. [PMID: 30762300 DOI: 10.1002/cam4.2014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
633 Zhu J, Sharma DB, Gray SW, Chen AB, Weeks JC, Schrag D. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA 2012;307:1593-601. [PMID: 22511687 DOI: 10.1001/jama.2012.454] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 8.8] [Reference Citation Analysis]
634 Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE 3rd, O'Day SJ. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012;30:34-41. [PMID: 22124101 DOI: 10.1200/JCO.2011.34.6270] [Cited by in Crossref: 112] [Cited by in F6Publishing: 69] [Article Influence: 10.2] [Reference Citation Analysis]
635 Jacoby JJ, Erez B, Korshunova MV, Williams RR, Furutani K, Takahashi O, Kirkpatrick L, Lippman SM, Powis G, O'Reilly MS, Herbst RS. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J Thorac Oncol 2010;5:940-9. [PMID: 20512076 DOI: 10.1097/JTO.0b013e3181dc211f] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
636 Jung CY. Biopsy and mutation detection strategies in non-small cell lung cancer. Tuberc Respir Dis (Seoul) 2013;75:181-7. [PMID: 24348665 DOI: 10.4046/trd.2013.75.5.181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
637 Lu S, Ye M, Ding L, Tan F, Fu J, Wu B. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Oncotarget 2017;8:9996-10006. [PMID: 28036283 DOI: 10.18632/oncotarget.14310] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
638 Guo Y, Hou J, Luo Y, Wang D. Functional disruption of macrophage migration inhibitory factor (MIF) suppresses proliferation of human H460 lung cancer cells by caspase-dependent apoptosis. Cancer Cell Int 2013;13:28. [PMID: 23522304 DOI: 10.1186/1475-2867-13-28] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
639 Price TJ, Lipton L, McGreivy J, McCoy S, Sun YN, Rosenthal MA. Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. Br J Cancer 2008;99:1387-94. [PMID: 18971935 DOI: 10.1038/sj.bjc.6604723] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
640 Gadgeel SM. The optimal chemotherapy for stage III non-small cell lung cancer patients. Curr Oncol Rep 2011;13:272-9. [PMID: 21479993 DOI: 10.1007/s11912-011-0170-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
641 Goi T, Nakazawa T, Hirono Y, Yamaguchi A. The anti-tumor effect is enhanced by simultaneously targeting VEGF and PROK1 in colorectal cancer. Oncotarget 2015;6:6053-61. [PMID: 25788276 DOI: 10.18632/oncotarget.3474] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
642 Zhu YM, Azahri NS, Yu DC, Woll PJ. Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells. BMC Cancer. 2008;8:218. [PMID: 18671849 DOI: 10.1186/1471-2407-8-218] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
643 Mayer T, Lacy J, Baehring J. A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma. Clin Med Oncol 2008;2:455-9. [PMID: 21892317 DOI: 10.4137/cmo.s827] [Reference Citation Analysis]
644 Baxevanos P, Mountzios G. Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau? Ann Transl Med 2018;6:139. [PMID: 29862228 DOI: 10.21037/atm.2018.04.04] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
645 Rasco DW, Yan J, Xie Y, Dowell JE, Gerber DE. Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol 2010;5:1529-35. [PMID: 20631635 DOI: 10.1097/JTO.0b013e3181e9a00f] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
646 Donkor M, Jones HP. The Proposition of the Pulmonary Route as an Attractive Drug Delivery Approach of Nano-Based Immune Therapies and Cancer Vaccines to Treat Lung Tumors. Front Nanotechnol 2021;3:635194. [DOI: 10.3389/fnano.2021.635194] [Reference Citation Analysis]
647 Teng F, Zhang JX, Chen Y, Shen XD, Su C, Guo YJ, Wang PH, Shi CC, Lei M, Cao YO, Liu SQ. LncRNA NKX2-1-AS1 promotes tumor progression and angiogenesis via upregulation of SERPINE1 expression and activation of the VEGFR-2 signaling pathway in gastric cancer. Mol Oncol 2021;15:1234-55. [PMID: 33512745 DOI: 10.1002/1878-0261.12911] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
648 Wang WW, Zhou XL, Song YJ, Yu CH, Zhu WG, Tong YS. Combination of long noncoding RNA MALAT1 and carcinoembryonic antigen for the diagnosis of malignant pleural effusion caused by lung cancer. Onco Targets Ther 2018;11:2333-44. [PMID: 29731641 DOI: 10.2147/OTT.S157551] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
649 Ostoros G, Döme B, Strausz J, Tímár J. [Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer]. Magy Onkol 2010;54:137-43. [PMID: 20576590 DOI: 10.1556/MOnkol.54.2010.2.8] [Reference Citation Analysis]
650 Zhang N, Yin R, Zhou P, Liu X, Fan P, Qian L, Dong L, Zhang C, Zheng X, Deng S, Kuai J, Liu Z, Jiang W, Wang X, Wu D, Huang Y. DLL1 orchestrates CD8+ T cells to induce long-term vascular normalization and tumor regression. Proc Natl Acad Sci U S A 2021;118:e2020057118. [PMID: 34035167 DOI: 10.1073/pnas.2020057118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
651 Huang YC, Shen SM, Liu CY, Pavlidis S, Wang CL, Ko HW, Chung FT, Lin TY, Feng PH, Lee KY, Guo YK, Yang CT, Kuo CS. Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR-mutant and EGFR-wild type nonsquamous non-small cell lung cancer. Thorac Cancer 2018;9:1648-55. [PMID: 30259696 DOI: 10.1111/1759-7714.12875] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
652 Gildener-Leapman N, Ferris RL, Bauman JE. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol 2013;49:1089-96. [PMID: 24126223 DOI: 10.1016/j.oraloncology.2013.09.009] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 7.9] [Reference Citation Analysis]
653 Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010;10:130-7. [PMID: 20094047 DOI: 10.1038/nrc2787] [Cited by in Crossref: 508] [Cited by in F6Publishing: 470] [Article Influence: 42.3] [Reference Citation Analysis]
654 Gold KA, Kim ES, Wistuba II, Hong WK. Personalizing lung cancer prevention through a reverse migration strategy. Top Curr Chem 2013;329:221-40. [PMID: 22752582 DOI: 10.1007/128_2012_338] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
655 Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol 2017;35:2781-9. [PMID: 28609226 DOI: 10.1200/JCO.2016.71.9476] [Cited by in Crossref: 182] [Cited by in F6Publishing: 118] [Article Influence: 36.4] [Reference Citation Analysis]
656 Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, Schwartz AG, Vahakangas KH, Samet JM. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 2009;15:5646-61. [PMID: 19755392 DOI: 10.1158/1078-0432.CCR-09-0377] [Cited by in Crossref: 103] [Cited by in F6Publishing: 52] [Article Influence: 8.6] [Reference Citation Analysis]
657 Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol 2016;11:383-400. [PMID: 26706237 DOI: 10.1007/s11523-015-0402-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
658 Choudhury NJ, Young RJ, Sellitti M, Miller A, Drilon A. Lorlatinib and Bevacizumab Activity in ALK-Rearranged Lung Cancers After Lorlatinib Progression. JCO Precis Oncol 2020;4:PO. [PMID: 33283131 DOI: 10.1200/PO.20.00271] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
659 Chen S, Sun J, Zhao L, Sun Y, Jia D, Song Y, Luo J, Lei H, Liu N. Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment. Exp Ther Med 2021;21:62. [PMID: 33365062 DOI: 10.3892/etm.2020.9494] [Reference Citation Analysis]
660 Choi YY, Noh SH, Cheong JH. Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives. J Pathol Transl Med. 2016;50:1-9. [PMID: 26498010 DOI: 10.4132/jptm.2015.09.10] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
661 Guo R, Meng X, Wang F, Yu J, Xie Q, Zhao W, Zhu L, Kung HF, Yang Z, Li N. 68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases. Front Oncol 2021;11:766851. [PMID: 34900716 DOI: 10.3389/fonc.2021.766851] [Reference Citation Analysis]
662 Pietanza MC, Hellmann MD, Fiore JJ, Smith-Marrone S, Basch EM, Schwartz LH, Ginsberg MS, Shouery M, Newman SK, Shaw M, Rogak LJ, Lash AE, Hilden P, Kris MG. Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. J Thorac Oncol 2016;11:890-9. [PMID: 26964771 DOI: 10.1016/j.jtho.2016.02.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
663 Gyawali B, Prasad V. Same Data; Different Interpretations. J Clin Oncol 2016;34:3729-32. [PMID: 27573659 DOI: 10.1200/JCO.2016.68.2021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
664 Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317-327. [PMID: 20414205 DOI: 10.1038/nri2744] [Cited by in Crossref: 773] [Cited by in F6Publishing: 904] [Article Influence: 64.4] [Reference Citation Analysis]
665 Zhou T, Wu C, Zhang C, Li P, Dong H, Zhou X, Lu H, Qi C, Ling Y. A retrospective study of low-dose apatinib combined with S-1 in patients with advanced non-small cell lung cancer. J Thorac Dis 2019;11:1831-7. [PMID: 31285875 DOI: 10.21037/jtd.2019.05.33] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
666 Barr MP, Gray SG, Gately K, Hams E, Fallon PG, Davies AM, Richard DJ, Pidgeon GP, O'Byrne KJ. Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer. Mol Cancer 2015;14:45. [PMID: 25889301 DOI: 10.1186/s12943-015-0310-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 6.6] [Reference Citation Analysis]
667 Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA Jr, Barón AE, Franklin WA, Aisner DL, Varella-Garcia M, Camidge DR. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012;118:4502-11. [PMID: 22282022 DOI: 10.1002/cncr.27409] [Cited by in Crossref: 173] [Cited by in F6Publishing: 173] [Article Influence: 17.3] [Reference Citation Analysis]
668 Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open 2016;1:e000066. [PMID: 27843624 DOI: 10.1136/esmoopen-2016-000066] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
669 Chang Y, Liu S, Jiang Y, Hua L, Wen L. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, cis-G796s/cis-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report. Respiratory Medicine Case Reports 2022;36:101582. [DOI: 10.1016/j.rmcr.2022.101582] [Reference Citation Analysis]
670 Horn L, Sandler AB. Angiogenesis in the treatment of non-small cell lung cancer. Proc Am Thorac Soc 2009;6:206-17. [PMID: 19349490 DOI: 10.1513/pats.200807-066LC] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
671 Tamiya A, Yamazaki K, Boku N, Machida N, Kojima T, Taku K, Yasui H, Fukutomi A, Hironaka S, Onozawa Y. Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. Int J Clin Oncol. 2009;14:513-517. [PMID: 19967487 DOI: 10.1007/s10147-009-0911-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
672 Zer A, Leighl N. Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC. Front Oncol 2014;4:329. [PMID: 25505733 DOI: 10.3389/fonc.2014.00329] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
673 Barni S, Cabiddu M, Guarneri P, Lonati V, Petrelli F. The risk for anemia with targeted therapies for solid tumors. Oncologist 2012;17:715-24. [PMID: 22531357 DOI: 10.1634/theoncologist.2012-0024] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
674 Bondarenko IM, Ingrosso A, Bycott P, Kim S, Cebotaru CL. Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer. BMC Cancer 2015;15:339. [PMID: 25929582 DOI: 10.1186/s12885-015-1350-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
675 Ho QT, Kuo CJ. Vascular endothelial growth factor: Biology and therapeutic applications. The International Journal of Biochemistry & Cell Biology 2007;39:1349-57. [DOI: 10.1016/j.biocel.2007.04.010] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 6.5] [Reference Citation Analysis]
676 Tang Y, He Z, Zhu Q, Qiao G. The 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer management. J Thorac Dis 2014;6:S589-96. [PMID: 25349710 DOI: 10.3978/j.issn.2072-1439.2014.09.15] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
677 Huang K, Wen C, Lee Y, Chu F. Cloning and characterization of terpene synthase genes from Taiwan cherry. Tree Genetics & Genomes 2019;15. [DOI: 10.1007/s11295-019-1355-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
678 Sheng M, Zhao Y, Wang F, Li S, Wang X, Shou T, Luo Y, Tang W. Targeted drugs for unselected patients with advanced non-small-cell lung cancer: a network meta-analysis. J Thorac Dis 2016;8:98-115. [PMID: 26904218 DOI: 10.3978/j.issn.2072-1439.2016.01.28] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
679 Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. PLoS One 2013;8:e51780. [PMID: 23349675 DOI: 10.1371/journal.pone.0051780] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
680 Kotasek D, Tebbutt N, Desai J, Welch S, Siu LL, McCoy S, Sun YN, Johnson J, Adewoye AH, Price T. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC Cancer 2011;11:313. [PMID: 21791058 DOI: 10.1186/1471-2407-11-313] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
681 Seto T, Nosaki K, Shimokawa M, Toyozawa R, Sugawara S, Hayashi H, Murakami H, Kato T, Niho S, Saka H, Oki M, Yoshioka H, Okamoto I, Daga H, Azuma K, Tanaka H, Nishino K, Tohnai R, Yamamoto N, Nakagawa K. Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). J Immunother Cancer 2022;10:e004025. [PMID: 35105689 DOI: 10.1136/jitc-2021-004025] [Reference Citation Analysis]
682 Simon GR. Individualizing chemotherapy for non-small cell lung cancer (NSCLC) in the adjuvant and advanced setting: current status and future directions. Curr Treat Options Oncol 2008;9:300-12. [PMID: 19266288 DOI: 10.1007/s11864-008-0075-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
683 Suzuki H, Fukuhara M, Yamaura T, Mutoh S, Okabe N, Yaginuma H, Hasegawa T, Yonechi A, Osugi J, Hoshino M. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J Transl Med. 2013;11:97. [PMID: 23578144 DOI: 10.1186/1479-5876-11-97] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis